JPH0789806A - Method for thermally transpiring chemical agent - Google Patents
Method for thermally transpiring chemical agentInfo
- Publication number
- JPH0789806A JPH0789806A JP5256286A JP25628693A JPH0789806A JP H0789806 A JPH0789806 A JP H0789806A JP 5256286 A JP5256286 A JP 5256286A JP 25628693 A JP25628693 A JP 25628693A JP H0789806 A JPH0789806 A JP H0789806A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- heat
- heating
- conductive member
- containing body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Catching Or Destruction (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、加熱蒸散用薬剤含有体
を用いた薬剤の加熱蒸散方法に関し、更に詳しくは、殺
虫、殺菌、殺ダニ、防虫、忌避、芳香、消臭等を目的と
して、薬剤成分のみ、あるいは溶剤や添加剤と共に薬剤
を含有する加熱蒸散用薬剤含有体を発熱体によって加熱
する際、熱伝導性部材を介して間接的に加熱することに
より、薬剤を長期間に亘って安定して蒸散させる加熱蒸
散方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for heat-evaporating a drug using a drug-containing body for heat-evaporation, and more specifically for the purpose of insecticidal, sterilizing, acaricidal, insect-proof, repellent, aroma, deodorant, etc. When heating the drug-containing body for heating and evaporation containing only the drug component or the drug together with the solvent and the additive with the heating element, the drug is indirectly heated through the heat conductive member, so that the drug can be used for a long period of time. The present invention relates to a heating evaporation method for stable and stable evaporation.
【0002】[0002]
【従来の技術】従来、加熱蒸散製剤として、固体、液体
又はペースト状の薬剤を発熱体を用いて加熱蒸散させる
方法が知られており、その代表的な例は電気蚊取器であ
る。電気蚊取器は、薬剤を含有する殺虫マットを電気的
に加熱される発熱板上に載置し、薬剤を蒸散させて殺虫
等の目的に用いられるものであり、上記殺虫マットとし
ては、従来よりパルプや石綿等を主とする繊維板等の基
材に薬剤を保持させたものが用いられている。2. Description of the Related Art Conventionally, as a heat-evaporative preparation, a method of heat-evaporating a solid, liquid or pasty medicine using a heating element has been known, and a typical example thereof is an electric mosquito trap. The electric mosquito repellent is an insecticidal mat containing a drug placed on a heating plate that is electrically heated to evaporate the drug and is used for insecticidal purposes. Further, a base material such as a fiberboard mainly composed of pulp or asbestos, which holds a chemical, is used.
【0003】電気蚊取器に代表されるこの種殺虫マット
の加熱蒸散方法においては、薬剤成分の分解と蒸散速度
をいかに調整して薬剤を長時間安定して蒸散させるかと
いうことが問題になる。そこで、長時間に亘って薬剤成
分を安定して蒸散させるための徐放化剤として、従来種
々の化合物が知られている。例えば、ピレスロイド系殺
虫剤の徐放化剤としては、ピペロニルブトキサイドやス
テアリン酸ブチル等が実際に使用されているが、十分満
足し得る薬剤蒸散調節はできていない。一方、有効成分
の分解を抑制する方法としては、一般に酸化防止剤の配
合が知られており、特開昭53−121927号公報に
は種々の有効な酸化防止剤が開示されている。しかしな
がら、このような方策をとっても、加熱使用後の有効成
分の残存率は高く、有効成分の充分な有効利用の点でな
お課題が残っている。すなわち、従来の加熱蒸散装置に
おいては、薬剤を含有するマットを直に発熱板上に載置
して加熱するため、マット全体が必要以上に常時高温状
態に置かれ、発熱板に接触している面だけでなくマット
の上面からも有効成分が蒸散する。そのため、加熱初期
の薬剤蒸散量が多く、その後は蒸散量が著しく減少し、
長時間に亘って安定した蒸散が得られず、それに伴って
効力の低下が見られ、また薬剤残存率も高くなる。In the heat evaporation method of this insecticidal mat represented by an electric mosquito trap, how to decompose the drug components and adjust the evaporation rate to stably evaporate the drug for a long time becomes a problem. . Therefore, various compounds have been conventionally known as sustained-release agents for stably evaporating a drug component over a long period of time. For example, piperonyl butoxide, butyl stearate and the like are actually used as sustained-release agents for pyrethroid insecticides, but the transpiration control of the drug is not sufficiently satisfactory. On the other hand, as a method for suppressing the decomposition of the active ingredient, it is generally known to blend an antioxidant, and Japanese Patent Application Laid-Open No. 53-121927 discloses various effective antioxidants. However, even if such a measure is taken, the residual rate of the active ingredient after heating and use is high, and a problem still remains in terms of sufficient effective use of the active ingredient. That is, in the conventional heating evaporation device, since the mat containing the drug is directly placed on the heating plate and heated, the entire mat is always kept in a higher temperature than necessary and is in contact with the heating plate. The active ingredient evaporates not only from the surface but also from the upper surface of the mat. Therefore, the amount of chemical vaporization in the early stage of heating is large, and after that, the amount of vaporization is significantly reduced
Stable transpiration cannot be obtained over a long period of time, the efficacy is reduced, and the residual rate of the drug is increased.
【0004】また、発熱板の温度分布を詳細に観察する
と、一般に発熱板の表面温度は均一でなく、中央部と周
辺部とで表面温度差が見られ、例えば発熱板中央部の表
面温度が170℃である場合にその周辺部の表面温度は
130℃程度となっている。そのため、マット中央部の
局部加熱を生じ、有効成分の熱分解が発生したり、薬剤
蒸散効率の低下や効力低下等が見られる一因となってい
る。さらに、従来の発熱板は、上記のように表面温度が
均一でないため、表面温度の高い中央部分と接触するマ
ットの対応部分からの薬剤蒸散が多くなり、その部分の
薬剤濃度が極めて希薄となる。そのため、薬剤の殆んど
がマットの下面中央部分に移動してきて蒸散することに
なり、この場合、薬剤はマットの縦及び横方向への移動
が必要となり、移動距離も長くなり、薬剤蒸散のための
スムーズな薬剤供給ひいては安定した薬剤蒸散が困難と
なる一因となっている。また、薬剤の蒸散がその部分に
おいて集中して行われるため、薬剤の熱分解等が起こり
易く、目詰り現象が生じてそれ以降の薬剤のスムーズな
蒸散を阻害するようになるという問題がある。Further, when the temperature distribution of the heat generating plate is observed in detail, generally the surface temperature of the heat generating plate is not uniform, and there is a difference in surface temperature between the central part and the peripheral part. For example, the surface temperature of the central part of the heat generating plate is When the temperature is 170 ° C, the surface temperature of the peripheral portion is about 130 ° C. As a result, local heating of the central part of the mat occurs, which causes thermal decomposition of the active ingredient, and causes a decrease in drug evaporation efficiency and a decrease in efficacy. Further, in the conventional heat generating plate, since the surface temperature is not uniform as described above, the amount of chemical evaporation from the corresponding portion of the mat that contacts the central portion having a high surface temperature is large, and the concentration of the chemical in that portion is extremely dilute. . Therefore, most of the chemicals move to the central portion of the lower surface of the mat and evaporate. In this case, the chemicals need to move in the vertical and horizontal directions of the mat, and the moving distance becomes long, so that the chemical evaporation This is one of the factors that make it difficult to smoothly supply the drug and thus to stably evaporate the drug. Further, since the evaporation of the drug is concentrated in that portion, thermal decomposition of the drug is likely to occur, and a clogging phenomenon occurs, which hinders smooth evaporation of the drug thereafter.
【0005】上記のような問題を回避し、長期間に亘っ
て安定した薬剤蒸散を得る方策として、薬液中に加熱蒸
散体の一部を浸漬することにより該加熱蒸散体に薬液を
吸液すると共に、その上部を加熱することにより吸液さ
れた薬液を蒸散させる方式、いわゆる薬液吸液式の加熱
蒸散方法が種々提案されている。このような薬液吸液式
の加熱蒸散方法では、加熱蒸散体(吸液芯)の上部を加
熱するために、筒状の発熱体を、吸液芯の上部周囲を周
隙を存して取り囲むように設置している(特公平4−1
1172号公報)。しかしながら、吸液芯は発熱体との
間に空気を介在させて間接的に加熱されるため、発熱体
自体の温度分布をわずかに緩衝するものの、薬剤は発熱
体近傍に位置し、長期に亘って加熱されると、吸液芯上
部の被加熱部で薬剤劣化が起こり、経時的蓄積による目
詰り現象が生じて、蒸散終了付近での薬剤のスムーズな
蒸散が阻害される傾向にある。また、吸液芯のサイズ、
つまり薬剤蒸散の表面積(被加熱面積)が発熱体形状
(筒状放熱部の径及び長さ)によって制約されるため、
薬剤蒸散面積を大きくして大量蒸散化させることが実質
的に困難なものとなっていた。更に薬剤の少量蒸散化
や、薬剤の種類が比較的低温で蒸散するものの場合、加
熱蒸散装置の発熱体温度を変更するか、又は発熱体と吸
液芯のかみ合い距離を短かくして、被加熱面積を小さく
する必要があった。しかし、被加熱面積を小さくする
と、薬剤蒸散量に対して吸液芯の長さや発熱体温度が及
ぼす影響度が大きく、製品としての品質を保証するため
にはかなり歩止まりが悪くなるという欠点を有してお
り、加熱蒸散装置を共有することには限界があった。前
述した発熱板上に直に薬剤蒸散体を載置する形式の場合
も、薬剤蒸散体のサイズは発熱体形状により制約される
ものであった。As a measure for avoiding the above problems and obtaining stable drug evaporation over a long period of time, a part of the heating evaporator is immersed in the solution to absorb the solution into the heating evaporator. At the same time, various methods of heating and vaporizing the absorbed chemical liquid by heating the upper part thereof, so-called chemical liquid absorption type heat vaporization methods have been proposed. In such a chemical liquid absorption-type heat evaporation method, in order to heat the upper part of the heat evaporation body (liquid absorption core), a cylindrical heating element is surrounded by a space around the upper part of the liquid absorption core. It is installed like
1172). However, since the liquid absorbent core is indirectly heated by interposing air between the liquid absorbent core and the heating element, it slightly buffers the temperature distribution of the heating element itself, but the drug is located near the heating element, and it remains for a long time. When heated by heating, the drug is deteriorated in the heated portion above the liquid absorbent core, and a clogging phenomenon occurs due to accumulation over time, which tends to hinder the smooth evaporation of the drug near the end of evaporation. Also, the size of the absorbent core,
That is, since the surface area (heated area) of the chemical evaporation is limited by the shape of the heating element (diameter and length of the cylindrical heat radiating portion),
It has been practically difficult to increase the chemical vaporization area and to vaporize a large amount. Furthermore, in the case where a small amount of the drug is vaporized or the type of the drug is vaporized at a relatively low temperature, change the heating element temperature of the heating evaporation device or shorten the meshing distance between the heating element and the liquid absorption core to reduce the heated area. Had to be smaller. However, if the area to be heated is made small, the influence of the length of the liquid absorbent core and the temperature of the heating element on the amount of chemical evaporation will be great, and the yield will deteriorate considerably in order to guarantee the quality of the product. However, there was a limit to sharing the heating evaporation device. Even in the case of the above-described type in which the drug vaporizer is directly placed on the heat generating plate, the size of the drug vaporizer is limited by the shape of the heat generator.
【0006】[0006]
【発明が解決しようとする課題】このように、電気的に
加熱される発熱体を使用する場合、薬剤蒸散体を均一に
加熱することは非常に困難であり、温度分布を生じ易
く、その結果、高温部における薬剤の劣化が激しく、経
時的に劣化した薬剤が薬剤蒸散体に蓄積し、薬剤蒸散に
悪影響を与えるため、長期間に亘って安定した所期の薬
剤効果が得られず、効力が低下すると共に薬剤残存率も
高くなっていた。更に、蒸散させる薬剤及び単位時間当
たりの薬剤蒸散量も発熱体によって制約されるものであ
った。また、蒸散した薬剤についても、加熱蒸散用器具
表面の低温部において薬剤付着を生じ易く、薬剤の実質
的蒸散量が低下するという問題があった。一般に、蒸散
した薬剤が温度の低い物体(器具の壁等)に接触する
と、薬剤凝結現象を生じ易くなり、ひいては薬剤の有効
蒸散率が低下し、所期の薬剤効果が得られなくなる。As described above, when an electrically heated heating element is used, it is very difficult to uniformly heat the drug vaporizer, and a temperature distribution is likely to occur. , The drug is severely deteriorated in the high temperature part, and the drug that deteriorates with time accumulates in the drug vaporizer, which adversely affects the drug evaporation, so that the desired drug effect cannot be obtained for a long period of time, and the efficacy is high. And the residual rate of the drug also increased. Further, the drug to be evaporated and the amount of drug evaporated per unit time are also limited by the heating element. Further, with respect to the evaporated drug, there is a problem that the drug is likely to adhere to the low temperature portion of the surface of the device for heating and evaporating, and the substantial amount of the drug is reduced. In general, when the evaporated drug comes into contact with an object having a low temperature (such as the wall of a device), the drug condensation phenomenon is likely to occur, which eventually lowers the effective evaporation rate of the drug, and the desired drug effect cannot be obtained.
【0007】したがって、本発明の目的は、薬剤の加熱
蒸散における前記のような問題を解消し、薬剤含有体を
均一に加熱し、薬剤の熱分解や薬剤含有体の目詰り等の
劣化を防止し、長期間に亘って薬剤を安定に且つ有効に
蒸散でき、有効蒸散率に優れた薬剤の加熱蒸散方法を提
供することにある。更に本発明の目的は、発熱体の形状
や加熱蒸散装置の形状に制約されずに薬剤含有体形状を
任意に設定でき、薬剤の種類や単位時間当たりの薬剤蒸
散量を自在に設定できる薬剤の加熱蒸散方法を提供する
ことにある。Therefore, the object of the present invention is to solve the above-mentioned problems in the heat evaporation of the drug, to uniformly heat the drug-containing body, and to prevent the thermal decomposition of the drug and the deterioration of the drug-containing body such as clogging. However, it is an object of the present invention to provide a method for heating and evaporating a drug which can stably and effectively evaporate the drug over a long period of time and has an excellent effective evaporation rate. Furthermore, the object of the present invention is not limited by the shape of the heating element or the shape of the heating evaporation device, the shape of the drug-containing body can be arbitrarily set, and the kind of the drug and the amount of the drug evaporated per unit time can be freely set. It is to provide a heating evaporation method.
【0008】[0008]
【課題を解決するための手段】前記目的を達成するため
に、本発明によれば、薬剤を含有する薬剤含有体を発熱
体により加熱するに際して、薬剤含有体と発熱体との間
に熱伝導性部材を発熱体に接触又は近接して設置し、該
熱伝導性部材を介して、即ち該熱伝導性部材に伝達した
熱によって薬剤含有体を直接あるいは間接的に加熱し、
薬剤を蒸散させることを特徴とする薬剤の加熱蒸散方法
が提供される。したがって、本発明によれば、熱源とな
る発熱体の形状に制約されない薬剤含有体の形状におい
て、薬剤を蒸散させる方法が提供される。本発明の一つ
の好適な態様によれば、熱伝導性部材及び/又は他の保
護部材により薬剤含有体の周囲を概略囲繞し、加熱の際
に薬剤含有体の少なくとも一部の表面の周囲に下方及び
/又は側方より上方へ向かう熱上昇気流が生じるように
上記熱伝導性部材及び/又は保護部材内に連通する空間
が形成される。また、上記熱伝導性部材を分割状体に形
成し、熱伝導性部材の各分割セグメントが可動であっ
て、弾性付勢力又は重力により発熱体に圧接又は接触さ
れるように構成することもできる。より好適には、熱伝
導性部材は縦割分割筒状体に形成される。In order to achieve the above object, according to the present invention, when a drug-containing body containing a drug is heated by a heating element, heat conduction between the drug-containing body and the heating element is achieved. A conductive member in contact with or close to a heating element, and directly or indirectly heats the drug-containing body through the heat conductive member, that is, by the heat transferred to the heat conductive member,
There is provided a method for heat evaporation of a drug, which comprises evaporating the drug. Therefore, according to the present invention, there is provided a method for evaporating a drug in the shape of the drug-containing body which is not restricted by the shape of the heat generating body serving as a heat source. According to one preferred embodiment of the present invention, a thermally conductive member and / or other protective member substantially surrounds the periphery of the drug-containing body, and when heated, it surrounds at least part of the surface of the drug-containing body. A space that communicates with the heat conductive member and / or the protection member is formed so that an upward heat flow from the lower side and / or the side direction is generated. In addition, the heat conductive member may be formed in a divided body, and each divided segment of the heat conductive member may be movable so as to be pressed against or contact with the heating element by elastic biasing force or gravity. . More preferably, the heat conductive member is formed in a vertically split cylindrical body.
【0009】[0009]
【発明の作用及び効果】本発明の薬剤の加熱蒸散方法
は、従来の殺虫マットのように薬剤を含有する基材を発
熱体上で直接接触した状態で基材の発熱体面側を直に加
熱する構成とは異なり、熱伝導性部材及び必要に応じて
他の保護部材を用いて、薬剤含有体を実質的に間接的に
加熱するようにしたものである。該熱伝導性部材は、発
熱体に接触又は近接して設置され、薬剤含有体は発熱体
の熱が伝達された熱伝導性部材を介して加熱されるた
め、熱伝導性部材が形成するいわゆる均熱部によって、
より均一に加熱することが可能になる。更に、熱伝導性
部材及び/又は保護部材により薬剤含有体の周囲を概略
囲繞し、薬剤含有体の発熱体面側だけでなく、多面に亘
って加熱できる構成とすることにより、薬剤含有体の被
加熱面積を大きくとることが可能となる。すなわち、薬
剤含有体の被加熱面積が大きくなることにより、局部的
な高温加熱の必要性がなくなり、薬剤含有体の被加熱部
分の温度を発熱体表面の最高温度よりかなり低目の均一
な温度に設定できる。According to the method of heating and evaporating a drug of the present invention, the base material containing the drug, such as a conventional insecticidal mat, is heated directly on the surface of the base material in direct contact with the base material. Unlike the configuration described above, the drug-containing body is substantially indirectly heated by using a heat conductive member and, if necessary, another protective member. The heat conductive member is installed in contact with or close to the heat generating element, and the drug-containing body is heated via the heat conductive member to which the heat of the heat generating element is transferred. By the soaking section,
It becomes possible to heat more uniformly. Further, by covering the periphery of the drug-containing body with a heat conductive member and / or a protection member so that the drug-containing body can be heated not only on the heating body surface side but also on multiple surfaces, the drug-containing body can be covered. It becomes possible to take a large heating area. That is, by increasing the heated area of the drug-containing body, the need for local high-temperature heating is eliminated, and the temperature of the heated part of the drug-containing body is much lower than the maximum temperature of the surface of the heating element. Can be set to.
【0010】その結果、加熱時の薬剤の熱分解を抑制で
き、薬剤含有体の蒸散面の目詰り等の劣化を抑制し、高
い有効蒸散率で長期間に亘って安定した薬剤蒸散が可能
となる。また、薬剤含有体は、熱伝導性部材及び/又は
保護部材によって均一に加熱されると共に、高い保温効
果を生み出す構成となっており、有効に薬剤を蒸散させ
ることができる。更に、薬剤含有体を加熱するに際し
て、熱伝導性部材を介して発熱体の熱を伝えるため、発
熱体形状による制約を受けずに薬剤含有体の形状・サイ
ズを任意に設定でき、しかも、発熱体から伝わる熱量も
任意に設定できるため、薬剤の種類や単位時間当たりの
薬剤蒸散量の調整が容易に行えるようになる。As a result, thermal decomposition of the drug during heating can be suppressed, deterioration of the evaporation surface of the drug-containing body such as clogging can be suppressed, and stable drug evaporation can be achieved for a long period of time with a high effective evaporation rate. Become. In addition, the drug-containing body is uniformly heated by the heat conductive member and / or the protective member and has a structure that produces a high heat retention effect, and the drug can be effectively evaporated. Further, when the drug-containing body is heated, the heat of the heat-generating body is transmitted through the heat conductive member, so that the shape and size of the drug-containing body can be arbitrarily set without being restricted by the shape of the heat-generating body. Since the amount of heat transferred from the body can be set arbitrarily, the type of drug and the amount of drug evaporated per unit time can be easily adjusted.
【0011】また、熱伝導性部材及び/又は保護部材に
より薬剤含有体の周囲を概略囲繞する構成にあっては、
熱伝導性部材及び/又は保護部材の下方又は側方を開口
させ、上方に薬剤蒸散口を開口して、薬剤含有体周囲に
連通する空間を形成することにより、熱上昇気流をスム
ーズに生じさせ、蒸散薬剤を有効に拡散(蒸散)でき
る。しかも、熱伝導性部材及び/又は保護部材が持つ高
い保温性により、蒸散薬剤が加熱蒸散用器具表面に付着
することを防止し、器具の汚染がなく、薬剤の有効蒸散
率も向上し、長期間に亘って所期の薬剤蒸散効果が維持
できる。また、薬剤含有体は、熱伝導性部材及び/又は
保護部材により概略囲繞された構成であるため、使用時
及び保管時に直接、薬剤含有体を手で触れないようにで
き、子供(幼児)が薬剤含有体を誤食又は誤飲すること
も防止でき、チャイルドプルーフ性が向上する。また、
その取り扱いは、容器を持って行なわれ、薬剤含有体
(薬剤)に直接手を触れる必要がないため安全であり、
特に皮膚の弱い小児に対しても安全であり、さらに衝撃
等にも強く、薬剤保護の面でも有利である。更に、薬剤
含有体に直接日光照射を受ける面を少なくでき、使用時
及び保管時の耐光性も向上し、薬剤が光によって分解す
ることを防止して、長期間に亘って安定した薬剤蒸散効
果が得られる。Further, in the constitution in which the periphery of the drug-containing body is roughly surrounded by the heat conductive member and / or the protection member,
By opening the lower side or side of the heat conductive member and / or the protective member and opening the drug evaporating port on the upper side to form a space communicating with the periphery of the drug-containing body, a heat rising airflow can be generated smoothly. , It is possible to effectively diffuse (evaporate) the evaporated drug. Moreover, due to the high heat retaining property of the heat conductive member and / or the protective member, it is possible to prevent the evaporated drug from adhering to the surface of the heating evaporation device, to prevent the device from being contaminated and to improve the effective evaporation rate of the drug. The desired drug evaporation effect can be maintained over a period of time. Moreover, since the drug-containing body is configured to be substantially surrounded by the heat conductive member and / or the protective member, it is possible to prevent the drug-containing body from being directly touched during use and storage, so that a child (infant) can Accidental ingestion or accidental ingestion of the drug-containing body can be prevented, and the child-proof property is improved. Also,
It is safe to handle because it does not need to touch the drug-containing body (medicine) directly with the container.
In particular, it is safe even for children with weak skin, and is also strong against impacts and the like, which is advantageous in terms of drug protection. Furthermore, the surface of the drug-containing body that is directly exposed to sunlight can be reduced, the light resistance during use and storage is improved, and the drug is prevented from being decomposed by light, resulting in a stable drug evaporation effect over a long period of time. Is obtained.
【0012】[0012]
【発明の態様】本発明で用いることのできる熱伝導性部
材としては薬剤蒸散に必要な熱量を伝えられるものであ
ればよく、銀、銅、金、アルミニウム、黄銅、タングス
テン、鉄、ニッケル、コバルト、亜鉛、マンガン、ジュ
ラルミン、ステンレス、真ちゅう等の金属、酸化アルミ
ニウム、酸化ケイ素、酸化マグネシウム、酸化バリウム
等のセラミック等が例示できる。また、薬剤の種類や発
熱体への設置位置によっては、後述する保護部材として
挙げる材料を熱伝導性部材としてもよい。また、熱伝導
性部材の形状は、薬剤含有体及び加熱蒸散装置の発熱体
形状によって任意に設定されるが、熱伝導性部材の少な
くとも一部が発熱体に接触あるいは近接して薬剤含有体
を間接的に加熱できる構造であればよい。また、発熱体
からの熱を有効利用するために、熱伝導性部材の表面を
断熱材等で覆うことにより熱損失を防ぎ、熱効率を向上
させることも可能である。DETAILED DESCRIPTION OF THE INVENTION As the heat conductive member which can be used in the present invention, any member can be used as long as it can transfer the amount of heat necessary for evaporation of the drug, and silver, copper, gold, aluminum, brass, tungsten, iron, nickel, cobalt. Examples include metals such as zinc, manganese, duralumin, stainless steel, brass, and ceramics such as aluminum oxide, silicon oxide, magnesium oxide, and barium oxide. Further, depending on the type of the medicine and the position where the medicine is installed on the heating element, the materials mentioned below as the protective member may be used as the heat conductive member. Further, the shape of the heat conductive member is arbitrarily set depending on the shape of the drug-containing body and the heating element of the heating evaporation device, but at least a part of the heat-conductive member is in contact with or close to the heating element to remove the drug-containing body. Any structure can be used as long as it can be indirectly heated. Further, in order to effectively use the heat from the heating element, it is possible to prevent the heat loss and improve the thermal efficiency by covering the surface of the heat conductive member with a heat insulating material or the like.
【0013】本発明に用いられる保護部材の材質として
は、使用される薬剤に応じ、耐熱性・耐薬剤性を有する
事が望まれる。例えば、ポリプロピレン、ポリエチレ
ン、ポリアミド、ポリエチレンテレフタレート、ポリブ
チレンテレフタレート、ポリサルフォン、ポリアセター
ル、メラミン樹脂、ポリ四フッ化エチレン、フェノール
樹脂、不飽和ポリエステル樹脂、エポキシ樹脂、ウレタ
ン樹脂、メタアクリル酸樹脂、ポリアリレート、ポリケ
トン、ポリアミドイミド、ポリアリルサルフォン、ポリ
フェニレンサルファイド、ポリフェニルサルフォン、ポ
リエーテルニトリル等が挙げられる。その他、これらに
アルミニウム等の金属粉末を練り込んだり金属蒸着した
もの等も利用できる。The material of the protective member used in the present invention is desired to have heat resistance and chemical resistance depending on the chemicals used. For example, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, polyacetal, melamine resin, polytetrafluoroethylene, phenol resin, unsaturated polyester resin, epoxy resin, urethane resin, methacrylic acid resin, polyarylate, Examples thereof include polyketone, polyamideimide, polyallyl sulfone, polyphenylene sulfide, polyphenyl sulfone, and polyether nitrile. In addition, a material obtained by kneading a metal powder of aluminum or the like or vapor-depositing a metal can also be used.
【0014】本発明の熱伝導性部材を介した加熱蒸散方
法は、薬剤含有体を発熱板上に載置して薬剤を蒸散させ
る方式、あるいは薬液中に加熱蒸散体の一部を浸漬し
て、薬液を吸液すると共にその上部を加熱することによ
り薬液を蒸散させる方式等に適用することが可能であ
り、しかも、これらの方式に拘わらず、各種形状の発熱
体を利用することが可能である。本発明の加熱蒸散方法
のより好適な蒸散方式を述べるとするならば、薬剤の
み、あるいは必要最小限の溶剤や添加剤と共に薬剤を含
有する薬剤含有体を、発熱体を熱源として、熱伝導性部
材を介して均一に加熱する方式が挙げられるが、このと
きの発熱体形状は前述した通り何ら制限されない。The method of heating and evaporating via the heat conductive member of the present invention is a method in which the drug-containing body is placed on a heating plate to evaporate the drug, or a part of the heat-evaporator is immersed in a chemical solution. It is possible to apply the method of evaporating the chemical solution by absorbing the chemical solution and heating the upper part thereof, and moreover, regardless of these methods, it is possible to use heating elements of various shapes. is there. Speaking of a more preferable evaporation method of the heating evaporation method of the present invention, only the drug, or a drug-containing body containing the drug together with the minimum necessary solvent and additives, the heat-generating body as a heat source, heat conductivity A method of uniformly heating through a member may be mentioned, but the shape of the heating element at this time is not limited as described above.
【0015】このように薬剤成分のみあるいは必要最小
限の溶剤を含有した高濃度の薬剤を蒸散させることは、
従来の薬液吸液式の加熱蒸散方式よりも熱効率が良好で
あるので、より好ましい。すなわち、薬液吸液式の場
合、薬剤の蒸散だけでなく溶剤の蒸散も必要とするた
め、不必要な熱を使用しており、所望の効果が得られる
蒸散量に達するまで時間を要する。それに比べて、薬剤
のみあるいは最小限の溶剤と共に薬剤を蒸散させる方式
では、薬剤の蒸散のみに熱を必要とするため非常に熱効
率が良好であり、より少ない熱量で薬剤の蒸散が可能と
なり、発熱体の消費電力が少なく、省エネルギー化が可
能になると共に、発熱体への通電直後から素早く薬剤含
有体が加熱され、薬剤蒸散の立ち上がりが非常に良好と
なり、例えば殺虫剤を加熱蒸散する場合においては、使
用初期から安定した殺虫効果が得られる。また、不必要
に溶剤を用いないので、液漏れを引き起こすことがな
く、非常にコンパクトな設計が可能になると共に、薬剤
成分のみ、あるいは溶剤を用いる場合でも必要最小限で
しか使用していないので、溶剤を蒸散させることによる
大気への悪影響を著しく低減させることが可能となる意
味で好ましい。In this way, it is possible to evaporate a high-concentration drug containing only the drug component or the minimum necessary solvent.
It is more preferable because it has better thermal efficiency than the conventional chemical vapor absorption type heating evaporation method. That is, in the case of the chemical liquid absorption type, not only the evaporation of the drug but also the evaporation of the solvent is required, so unnecessary heat is used, and it takes time to reach the amount of evaporation to obtain the desired effect. On the other hand, in the method of evaporating the drug only with the drug or with the minimum solvent, the heat is required only for the evaporation of the drug, so that the thermal efficiency is very good, and the drug can be evaporated with a smaller amount of heat, and the heat generation is reduced. The power consumption of the body is low, and it is possible to save energy, and the drug-containing body is quickly heated immediately after the heating element is energized, and the rise of drug evaporation becomes very good. For example, in the case of heating and evaporating an insecticide, , A stable insecticidal effect is obtained from the beginning of use. In addition, since the solvent is not used unnecessarily, liquid leakage does not occur, and a very compact design is possible, and even when only the drug component or the solvent is used, it is used only at the minimum necessary. In the sense that it is possible to significantly reduce the adverse effect on the atmosphere due to evaporation of the solvent.
【0016】本発明の加熱蒸散方法において、好適に用
いられる加熱蒸散用薬剤含有体は、無機粉末及び/又は
有機粉末を基材として薬剤を含浸、塗布等によって含有
させたものであり、基材としてはリン酸水素カルシウム
及びその無水物、リン酸カルシウム、リン酸カルシウム
系アパタイト、メタケイ酸アルミン酸マグネシウム、ヒ
ドロタルシド、水酸化アルミニウムゲル、水酸化アルミ
ナ・マグネシウム、炭酸カルシウム、ケイ酸アルミニウ
ム、ケイ酸マグネシウム、無水ケイ酸、クレ−、ケイソ
ウ土、カオリン、コロイダルシリカ、水ガラス、リン酸
アルミニウム、リン酸マグネシウム、石膏、マグネシア
セメント、タングステン、酸化亜鉛、べんがら、三酸化
タングステン、酸化ジルコニウム等の無機粉末や、PT
FE(四フッ化エチレン樹脂)・PVdF(フッ化ビニ
リデン樹脂)等のフッ素系樹脂、ポリアセタ−ル、ポリ
アリレ−ト、ポリエ−テルエ−テルケトン、ポリエチレ
ン、ポリエチレンテレフタレ−ト、ポリカ−ボネ−ト、
ナイロン6・ナイロン66・ナイロン11・ナイロン1
2・芳香族ナイロンやそれらの共重合物等のポリアミ
ド、ポリイミド、ポリアミドイミド、ポリサルホン・ポ
リエ−テルサルホン等のポリサルホン系樹脂、ポリフェ
ニレンエ−テル、ポリフェニレンサルファイド、ポリブ
チレンテレフタレ−ト、ポリプロピレン、ポリメチルペ
ンテン、AES樹脂、AS樹脂、ABS樹脂、MBS樹
脂、結晶セルロ−ス、CMC、MC、澱粉、HPMC、
HPC、HPS等の有機粉末が例示される。加熱蒸散用
薬剤含有体は、無機粉末及び/又は有機粉末を混合し、
圧縮成形、押出成形等の手法により調製することができ
るが、成形方法に関しては特に限定されるものでない。
また、本発明の加熱蒸散用薬剤含有体の形状は、平板
状、ドーナツ状、円柱状等任意である。In the heat evaporation method of the present invention, the drug-containing body for heat evaporation that is preferably used is obtained by impregnating or coating a drug with an inorganic powder and / or an organic powder as a base material. As calcium hydrogen phosphate and its anhydride, calcium phosphate, calcium phosphate-based apatite, magnesium metasilicate aluminate, hydrotalside, aluminum hydroxide gel, alumina hydroxide magnesium, calcium carbonate, aluminum silicate, magnesium silicate, anhydrous silicic acid Inorganic powder such as clay, diatomaceous earth, kaolin, colloidal silica, water glass, aluminum phosphate, magnesium phosphate, gypsum, magnesia cement, tungsten, zinc oxide, red iron oxide, tungsten trioxide, zirconium oxide, and PT.
Fluorine-based resins such as FE (tetrafluoroethylene resin) and PVdF (vinylidene fluoride resin), polyacetal, polyarylate, polyethylene ether ketone, polyethylene, polyethylene terephthalate, polycarbonate,
Nylon 6, Nylon 66, Nylon 11, Nylon 1
2. Polyamides such as aromatic nylon and copolymers thereof, polyimides, polyamideimides, polysulfone resins such as polysulfone / polyethersulfone, polyphenylene ether, polyphenylene sulfide, polybutylene terephthalate, polypropylene, polymethyl Penten, AES resin, AS resin, ABS resin, MBS resin, crystalline cellulose, CMC, MC, starch, HPMC,
Organic powders such as HPC and HPS are exemplified. The drug-containing body for heat evaporation is a mixture of inorganic powder and / or organic powder,
It can be prepared by methods such as compression molding and extrusion molding, but the molding method is not particularly limited.
The shape of the drug-containing body for heat evaporation of the present invention is arbitrary such as flat plate, donut shape, and columnar shape.
【0017】なお、有機粉末のうち、特に熱可塑性樹脂
粉末を用いた場合、薬剤含有体を成形後、熱可塑性樹脂
粉末の融点付近にて加熱融着させ、薬剤含有体の強度を
向上させることもできる。すなわち、熱可塑性樹脂粉末
が無機粉末及び/又は有機粉末と密着した状態でその接
触部分を融着させることにより、多孔性を失うことな
く、折れ及び割れに対する強度の向上が得られる。さら
に、熱可塑性樹脂粉末は、耐水性及び耐湿性にも優れて
いるので、高湿時においても強度低下を示さないため、
一般的使用の環境下においても一定の強度を保つ安定し
た品質の加熱蒸散用薬剤含有体の成形が可能である。ま
た、熱可塑性樹脂粉末は水に対して安定であるため、本
発明の加熱蒸散用薬剤含有体を用いることによって、水
ベースの消臭剤、防菌防黴剤、殺虫剤、香料等の水溶性
や乳化した薬液を蒸散することが可能となる。Among the organic powders, particularly when a thermoplastic resin powder is used, the strength of the drug-containing body is improved by molding the drug-containing body and then heat-sealing it near the melting point of the thermoplastic resin powder. You can also That is, by melting the contact portion of the thermoplastic resin powder in close contact with the inorganic powder and / or the organic powder, the strength against breakage and cracking can be obtained without losing the porosity. Furthermore, since the thermoplastic resin powder has excellent water resistance and moisture resistance, it does not exhibit strength reduction even at high humidity.
It is possible to mold a drug-containing body for heat vaporization of stable quality which maintains a constant strength even under an environment of general use. Further, since the thermoplastic resin powder is stable to water, by using the chemical substance for heat evaporation of the present invention, water-based deodorant, antibacterial and fungicide, insecticide, fragrance, etc. It is possible to evaporate the liquid medicine and the emulsified drug solution.
【0018】また、本発明の加熱蒸散用薬剤含有体に
は、圧縮成形時及び押出成形時の粉末の流動性や滑性・
滑沢性を向上させるために、加熱蒸散用薬剤含有体の特
性を損なわぬ範囲で必要に応じて滑剤、滑沢剤として、
タルク、ステアリン酸マグネシウム、ステアリン酸ナト
リウム等のステアリン酸塩、N−ラウリル−DL−アス
パラギン酸−β−ラウリルエステルやN6 −ラウロイル
−L−リジン等のアミノ酸系滑沢剤やホウ酸、流動パラ
フィン、安息香酸ナトリウム、カルボワックス等のワッ
クス類等を添加することもできる。さらに、加熱蒸散用
薬剤含有体の強度向上のために、ガラス繊維、カーボン
繊維等の繊維状粉体を添加することもできる。In addition, the drug substance for heat evaporation of the present invention contains the fluidity and lubricity of powder during compression molding and extrusion molding.
In order to improve the lubricity, if necessary, as a lubricant and a lubricant within a range that does not impair the characteristics of the agent containing heat for evaporation,
Talc, stearates such as magnesium stearate and sodium stearate, amino acid lubricants such as N-lauryl-DL-aspartic acid-β-lauryl ester and N 6 -lauroyl-L-lysine, boric acid, liquid paraffin It is also possible to add waxes such as sodium benzoate and carbowax. Further, fibrous powder such as glass fiber or carbon fiber may be added to improve the strength of the drug-containing body for heat evaporation.
【0019】なお、加熱蒸散用薬剤含有体には、その特
性を損なわない範囲で必要に応じて顔料、色素、防腐
剤、酸化防止剤、紫外線吸収剤、難燃剤、誤食防止剤等
の添加剤を配合してもよい。配合できる酸化防止剤とし
ては、ステアリル−β−(3,5−ジ−t−ブチル−4
−ヒドロキシフェニル)プロピオネート、2,2′−メ
チレンビス(4−メチル−6−t−ブチルフェノー
ル)、2,2′−メチレンビス(4−エチル−6−t−
ブチルフェノール)、4,4′−メチレンビス(2,6
−ジ−t−ブチルフェノール)、4,4′−ブチリデン
ビス(3−メチル−6−t−ブチルフェノール)、4,
4′−チオビス(3−メチル−6−t−ブチルフェノー
ル)、1,3,5−トリメチル−2,4,6−トリス
(3,5−ジ−t−ブチル−4−ヒドロキシベンジル)
ベンゼン、1,1,3−トリス−(2−メチル−4−ヒ
ドロキシ−5−t−ブチルフェニル)ブタン、テトラキ
ス−[メチレン−3−(3′,5′−ジ−t−ブチル−
4′−ヒドロキシフェニル)プロピオネート]メタン、
2−メルカプトベンズイミダゾール、1,1−ビス(4
−ヒドロキシフェニル)シクロヘキサン、N−フェニル
−β−ナフチルアミン、N,N′−ジフェニル−p−フ
ェニレンジアミン、2,2,4−トリメチル−1,2−
ジヒドロキノリンポリマー、6−エトキシ−2,2,4
−トリメチル−1,2−ジヒドロキノリン、2−t−ブ
チル−6−(3−t−ブチル−2−ヒドロキシ−5−メ
チルベンジル)−4−メチルフェニルアクリレート、
3,5−ジ−t−ブチル−4−ヒドロキシ−ベンジルフ
ォスフォネート−ジエチルエステル、ビス(3,5−ジ
−t−ブチル−4−ヒドロキシベンジルホスホン酸エチ
ル)カルシウム、トリス[2−(3′,5′−ジ−t−
ブチル−4′−ヒドロキシヒドロ−シンナモイルオキシ
ル)エチル]イソシアヌレート、トリスー(4−t−ブ
チル−2,6−ジ−メチル−3−ヒドロキシベンジル)
イソシアヌレート、3,9−ビス[1,1−ジ−メチル
−2−{β−(3−t−ブチル−4−ヒドロキシ−5−
メチルフェニル)プロピオニルオキシ}エチル]−2,
4,8,10−テトラオキサスピロ[5.5]ウンデカ
ン、ジトリデシル−3,3′−チオジプロピオネート、
ジミリスチル−3,3′−チオジプロピオネート、ジス
テアリル−3,3′−チオジプロピオネート、トリエチ
レングリコールービス[3−(3−t−ブチル−5−メ
チル−4−ヒドロキシフェニル)プロピオネート]、
1,6−ヘキサンジオール−ビス[3−(3,5−ジ−
t−ブチル−4−ヒドロキシフェニル)プロピオネー
ト]、N,N′−ヘキサメチレンビス(3,5−ジ−t
−ブチル−4−ヒドロキシ−ヒドロシンナマミド)、
2,2−チオ−ジエチレンビス[3−(3,5−ジ−t
−ブチル−4−ヒドロキシフェニル)プロピオネー
ト]、N、N′−ビス[3−(3,5−ジ−t−ブチル
−4−ヒドロキシフェニル)プロピオニル]ヒドラジ
ン、トリス−(3,5−ジ−t−ブチル−4−ヒドロキ
シベンジル)−イソシアヌレート、2,4−ビス−(n
−オクチルチオ)−6−(4−ヒドロキシ−3,5−ジ
−t−ブチルアニリノ)−1,3,5−トリアジン等の
化合物が例示される。これらは、単独でも、また2種以
上を組み合わせて混合使用することもできる。これら酸
化防止剤の添加により、加熱使用時における熱劣化防
止、酸化防止、薬剤の分解、重合防止、長期に亘る経時
安定性の向上などの効果が得られる。If necessary, pigments, dyes, preservatives, antioxidants, ultraviolet absorbers, flame retardants, and accidental food inhibitors are added to the heat-transpiration agent-containing body as long as its characteristics are not impaired. You may mix | blend an agent. As an antioxidant that can be blended, stearyl-β- (3,5-di-t-butyl-4
-Hydroxyphenyl) propionate, 2,2'-methylenebis (4-methyl-6-t-butylphenol), 2,2'-methylenebis (4-ethyl-6-t-)
Butylphenol), 4,4'-methylenebis (2,6
-Di-t-butylphenol), 4,4'-butylidenebis (3-methyl-6-t-butylphenol), 4,
4'-thiobis (3-methyl-6-t-butylphenol), 1,3,5-trimethyl-2,4,6-tris (3,5-di-t-butyl-4-hydroxybenzyl)
Benzene, 1,1,3-tris- (2-methyl-4-hydroxy-5-t-butylphenyl) butane, tetrakis- [methylene-3- (3 ', 5'-di-t-butyl-
4'-hydroxyphenyl) propionate] methane,
2-mercaptobenzimidazole, 1,1-bis (4
-Hydroxyphenyl) cyclohexane, N-phenyl-β-naphthylamine, N, N'-diphenyl-p-phenylenediamine, 2,2,4-trimethyl-1,2-
Dihydroquinoline polymer, 6-ethoxy-2,2,4
-Trimethyl-1,2-dihydroquinoline, 2-t-butyl-6- (3-t-butyl-2-hydroxy-5-methylbenzyl) -4-methylphenyl acrylate,
3,5-di-t-butyl-4-hydroxy-benzylphosphonate-diethyl ester, bis (3,5-di-t-butyl-4-hydroxybenzylphosphonate ethyl) calcium, tris [2- (3 ', 5'-di-t-
Butyl-4'-hydroxyhydro-cinnamoyloxyl) ethyl] isocyanurate, tris- (4-t-butyl-2,6-di-methyl-3-hydroxybenzyl)
Isocyanurate, 3,9-bis [1,1-di-methyl-2- {β- (3-t-butyl-4-hydroxy-5-
Methylphenyl) propionyloxy} ethyl] -2,
4,8,10-tetraoxaspiro [5.5] undecane, ditridecyl-3,3'-thiodipropionate,
Dimyristyl-3,3'-thiodipropionate, distearyl-3,3'-thiodipropionate, triethylene glycol-bis [3- (3-t-butyl-5-methyl-4-hydroxyphenyl) propionate ],
1,6-hexanediol-bis [3- (3,5-di-
t-Butyl-4-hydroxyphenyl) propionate], N, N′-hexamethylenebis (3,5-di-t
-Butyl-4-hydroxy-hydrocinnamamide),
2,2-thio-diethylenebis [3- (3,5-di-t
-Butyl-4-hydroxyphenyl) propionate], N, N'-bis [3- (3,5-di-t-butyl-4-hydroxyphenyl) propionyl] hydrazine, tris- (3,5-di-t -Butyl-4-hydroxybenzyl) -isocyanurate, 2,4-bis- (n
Examples thereof include compounds such as -octylthio) -6- (4-hydroxy-3,5-di-t-butylanilino) -1,3,5-triazine. These may be used alone or in combination of two or more. By adding these antioxidants, effects such as prevention of thermal deterioration during heating, prevention of oxidation, decomposition of chemicals, prevention of polymerization, and improvement of long-term stability over time can be obtained.
【0020】また、過酸化物分解剤と一般に呼ばれる酸
化防止剤、例えば、ジラウリルチオジプロピオネート
(DLTP)やジステアリルチオジプロピオネート(D
STP)等を、前記酸化防止剤と組み合わせて、混合使
用することもできる。さらに、安定剤として紫外線吸収
剤を用いることにより、保管時、使用時の耐光性を一段
と向上させることができる。Further, antioxidants generally called peroxide decomposers, such as dilauryl thiodipropionate (DLTP) and distearyl thiodipropionate (D
STP) and the like may be used in combination with the antioxidant. Further, by using an ultraviolet absorber as a stabilizer, the light resistance during storage and use can be further improved.
【0021】本発明の加熱蒸散方法の加熱温度は、含有
される薬剤により選択されるが、通常、加熱蒸散用薬剤
含有体の被加熱部表面温度を40℃〜200℃に保持す
ることが好ましい。また、前記発熱体の発熱方法として
は、抵抗ヒーター(ニクロム線等)・半導体(PTC)
を用いたヒーターに通電する方法、酸化反応(鉄・マグ
ネシウム等の金属の酸化等)、加水反応(生石灰と水の
反応等)、アルコール・ガス・灯油・ワックス等の燃焼
熱、また白金触媒を使用したアルコール・ガス等の燃焼
熱を利用する方法、及びその他の熱源を直接あるいは間
接的に利用する方法等が用いられる。The heating temperature of the heating and vaporizing method of the present invention is selected depending on the drug to be contained, but it is usually preferable to maintain the surface temperature of the heated portion of the drug-containing body for heating and vaporizing at 40 ° C to 200 ° C. . In addition, as a heat generation method of the heating element, a resistance heater (nichrome wire or the like), semiconductor (PTC)
A method of energizing a heater using, oxidation reaction (oxidation of metals such as iron and magnesium), hydrolysis reaction (reaction of quicklime and water, etc.), combustion heat of alcohol, gas, kerosene, wax, etc., and platinum catalyst A method of utilizing the combustion heat of the used alcohol or gas, a method of directly or indirectly utilizing other heat source, or the like is used.
【0022】本発明の加熱蒸散用薬剤含有体には、使用
目的に応じて種々の蒸散性薬剤を含有させることができ
る。例えば殺虫を目的として使用する場合、殺虫剤とし
ては、従来より用いられている各種蒸散性殺虫剤を用い
ることができ、ピレスロイド系殺虫剤、カーバメイト系
殺虫剤、有機リン系殺虫剤等を挙げることができる。一
般に安全性が高いことからピレスロイド系殺虫剤が好適
に用いられ、例えばアレスリン、d1・d−T80−ア
レスリン、d・d−T80−アレスリン、d・d−T8
0−プラレトリン、フタルスリン、d−T80−レスメ
トリン、d−T80−フラメトリン、ペルメトリン、フ
ェノトリン、フェンバレレート、シペルメトリン、シフ
ェノトリン、エムペントリン、テラレスリン、エトフェ
ンプロックス、ベンフルスリン等従来公知の各種ピレス
ロイド系殺虫剤を用いることができる。また同様に、芳
香を目的として使用する場合には、天然及び人工の各種
香料を用いることができ、例えば動物性、植物性の天然
香料、炭化水素、アルコール、フェノール、アルデヒ
ド、ケトン、ラクトン、オキシド、エステル類等の人工
香料などであり、これらの1種を単独で使用できる他、
2種以上を混合して使用することもできる。さらに、目
的に応じて消臭剤、殺菌剤、防バイ剤、防錆剤、殺ダニ
剤、忌避剤等の各種薬剤についても、加熱により蒸散す
る薬剤であれば使用できる。The heat-evaporative drug-containing body of the present invention may contain various evaporative drugs depending on the purpose of use. For example, when used for the purpose of insecticidal, as the insecticide, it is possible to use various transpiration insecticides that have been conventionally used, such as pyrethroid insecticides, carbamate insecticides, organophosphorus insecticides and the like. You can Generally, a pyrethroid insecticide is preferably used because it is highly safe, and examples thereof include allethrin, d1 · d-T80-allethrin, d · d-T80-allethrin, and d · d-T8.
Various conventionally known pyrethroid insecticides such as 0-praletrin, phthalthrin, d-T80-resmethrin, d-T80-flamethrin, permethrin, phenothrin, fenvalerate, cypermethrin, cifenotrin, empentrin, terrarethrin, etofenprox, benfluthrin and the like. Can be used. Similarly, when used for the purpose of aroma, various natural and artificial flavors can be used, for example, animal or plant natural flavors, hydrocarbons, alcohols, phenols, aldehydes, ketones, lactones, oxides. , Artificial flavors such as esters, etc., and one of these can be used alone,
It is also possible to use a mixture of two or more kinds. Furthermore, various chemicals such as deodorants, germicides, antibacterial agents, rust preventives, acaricides, and repellents can be used depending on the purpose, as long as they can be evaporated by heating.
【0023】そして、加熱蒸散用薬剤含有体に薬剤を含
有させる時点において、薬剤の滲透性あるいは拡散性を
向上させる目的で、必要最小限の溶剤を用いることもで
きる。溶剤としては、脂肪族飽和炭化水素系溶剤を用い
ることができる。市販されているものとしては、例え
ば、0号ソルべントH(日本石油株式会社製)、0号ソ
ルベントM(日本石油株式会社製)、ノルマルパラフィ
ン(三石・テキサコケミカル株式会社製)、IPソルベ
ント2028(出光石油化学株式会社製)などが挙げら
れる。また、不飽和脂肪族炭化水素系溶剤も用いること
ができる。その他、水、アルコール類、エチレングリコ
ールモノブチルエーテル等のグリコールエーテル類やグ
リコール類、IPM等のエステルも用いることができ
る。Then, at the time of incorporating the drug into the drug substance for heat evaporation, the minimum necessary solvent can be used for the purpose of improving the permeability or diffusibility of the drug. An aliphatic saturated hydrocarbon solvent can be used as the solvent. Examples of commercially available products include No. 0 solvent H (manufactured by Nippon Oil Co., Ltd.), No. 0 solvent M (manufactured by Nippon Oil Co., Ltd.), normal paraffin (Mitsuishi / Texaco Chemical Co., Ltd.), IP solvent 2028 (made by Idemitsu Petrochemical Co., Ltd.) and the like. Moreover, an unsaturated aliphatic hydrocarbon solvent can also be used. In addition, water, alcohols, glycol ethers such as ethylene glycol monobutyl ether, glycols, and esters such as IPM can be used.
【0024】以下、本発明の加熱蒸散方法の各種態様に
ついて具体的に説明する。図1は、本発明の加熱蒸散方
法の一具体例を示す。図中、1は薬剤含有体であり、2
は円板状の熱伝導性部材3とキャップ状の保護部材9と
からなる容器である。円板状の熱伝導性部材3の外周面
には複数個の台座部4が一体に形成され、またその上下
面には複数箇所において凸部5及び6が突設されてい
る。上記薬剤含有体1の外周面を熱伝導性部材3の台座
部4内面に摺接しながら嵌め込み、熱伝導性部材3の上
面の凸部5上に載置した状態で、キャップ状の保護部材
9を上記台座部4外面の係合段部7に嵌め合わせて固定
し、容器2を組み立てる。なお、熱伝導性部材3と保護
部材9の固定には他の任意の方法を用いることができ
る。容器2の下部には熱伝導性部材3の複数の台座部4
間の空隙により通気口8が形成され、また、キャップ状
の保護部材9の上面中央には蒸散口10が形成されてい
る。従って、薬剤含有体1を囲繞する熱伝導性部材3と
保護部材9とからなる容器2内には、下方の通気口8か
ら薬剤含有体1周辺を経て上方の蒸散口10へ連通する
空間が形成される。Hereinafter, various aspects of the heat evaporation method of the present invention will be specifically described. FIG. 1 shows a specific example of the heating evaporation method of the present invention. In the figure, 1 is a drug-containing body, and 2
Is a container including a disc-shaped heat conductive member 3 and a cap-shaped protection member 9. A plurality of pedestal portions 4 are integrally formed on the outer peripheral surface of the disc-shaped heat conductive member 3, and convex portions 5 and 6 are provided on the upper and lower surfaces thereof at a plurality of locations. The outer peripheral surface of the drug-containing body 1 is slidably fitted onto the inner surface of the pedestal portion 4 of the heat conductive member 3, and is placed on the convex portion 5 on the upper surface of the heat conductive member 3, and the cap-shaped protection member 9 is provided. Is fitted and fixed to the engaging stepped portion 7 on the outer surface of the pedestal portion 4, and the container 2 is assembled. Other arbitrary methods can be used to fix the heat conductive member 3 and the protection member 9. A plurality of pedestals 4 of the heat conductive member 3 are provided at the bottom of the container 2.
The air gap 8 is formed by the space between them, and the evaporation port 10 is formed in the center of the upper surface of the cap-shaped protection member 9. Therefore, in the container 2 composed of the heat-conductive member 3 surrounding the drug-containing body 1 and the protective member 9, there is a space communicating from the lower vent hole 8 to the upper evaporation port 10 through the periphery of the drug-containing body 1. It is formed.
【0025】以上のようにして組み立てられた薬剤含有
体1を収容した容器2は、加熱蒸散装置11に配設され
た板状発熱体12上に載置し、発熱体12を加熱して使
用する。発熱体12の発熱によって、熱伝導性部材3が
直接(下面の凸部6を介して)あるいは間接的に熱伝導
を受け、容器2の内部温度が上昇する。この温度上昇に
伴い、図中矢印で示すように、通気口8から薬剤含有体
1周辺を経て蒸散口10へ向かう熱上昇気流が発生し、
更に、全面に亘って均一に加熱された薬剤含有体1から
薬剤が蒸散し、上記熱上昇気流に乗ってスムーズに蒸散
口10より蒸散・拡散する。保護部材9は、薬剤含有体
1を保護していると共に、加熱時の保温材料としても機
能している。このため、容器自体が高い保温性をもち、
一度蒸散した薬剤が蒸散口10周辺に付着することを防
止する。なお、加熱蒸散装置11の底部及び発熱体12
周囲にも通気口13,14が形成されており、発熱体1
2の発熱に伴って図中矢印で示したような加熱蒸散装置
11内を通流する熱上昇気流も発生し、この熱上昇気流
は薬剤含有体1から蒸散された薬剤の拡散を促進すると
共に、上記蒸散した薬剤の蒸散口10周辺への付着防止
にも寄与する。The container 2 containing the drug-containing body 1 assembled as described above is placed on the plate-shaped heating element 12 provided in the heating evaporation device 11, and the heating element 12 is heated for use. To do. Due to the heat generated by the heating element 12, the heat conductive member 3 receives heat conduction directly (via the convex portion 6 on the lower surface) or indirectly, and the internal temperature of the container 2 rises. As this temperature rises, as shown by the arrow in the figure, a heat rising airflow is generated from the ventilation port 8 through the periphery of the drug-containing body 1 to the evaporation port 10,
Further, the drug evaporates from the drug-containing body 1 that is uniformly heated over the entire surface, and smoothly evaporates / diffuses from the evaporation port 10 by riding on the above-mentioned heat rising airflow. The protection member 9 protects the drug-containing body 1 and also functions as a heat retaining material during heating. Therefore, the container itself has high heat retention,
It prevents the once evaporated drug from adhering to the periphery of the evaporation port 10. The bottom of the heating evaporation device 11 and the heating element 12
Vents 13 and 14 are also formed in the periphery, and the heating element 1
Along with the heat generation of 2, a heat rising airflow that flows through the heating evaporation device 11 as shown by the arrow in the figure is also generated, and this heat rising airflow promotes the diffusion of the drug evaporated from the drug-containing body 1. Also, it contributes to the prevention of adhesion of the evaporated chemicals around the evaporation port 10.
【0026】図2は、図1に示す構成の変形例であり、
加熱蒸散装置の図示は省略している。この変形例におい
ては、リング状の薬剤含有体1aが用いられ、これが、
熱伝導性部材3aの中央孔15から上方に一体に突設さ
れた筒状体16のまわりに配置される。また、キャップ
状の保護部材9aの周壁には複数個のスリット状の通気
口8aが形成され、また上壁には複数箇所に蒸散口10
aが形成されている。従って、図2に示す構成の場合、
発熱体12の発熱によって容器2aの内部温度が上昇す
るに伴い、図中矢印で示すように、通気口8aから薬剤
含有体1a周辺を経て蒸散口10aに向かう熱上昇気流
が発生すると共に、発熱体12と熱伝導性部材3aとの
空隙部から筒状体16内の中央孔15を経て蒸散口10
aに向かう熱上昇気流も発生し、薬剤の蒸散・拡散をよ
りスムーズに行うことができる。FIG. 2 shows a modification of the configuration shown in FIG.
Illustration of the heating evaporation device is omitted. In this modified example, a ring-shaped drug containing body 1a is used, which is
The heat conductive member 3a is arranged around a cylindrical body 16 integrally projecting upward from the central hole 15 of the heat conductive member 3a. Further, a plurality of slit-shaped ventilation holes 8a are formed on the peripheral wall of the cap-shaped protection member 9a, and the evaporation holes 10 are formed at a plurality of positions on the upper wall.
a is formed. Therefore, in the case of the configuration shown in FIG.
As the internal temperature of the container 2a rises due to the heat generation of the heat generating body 12, as shown by the arrow in the figure, a heat rising airflow is generated from the ventilation hole 8a to the evaporation port 10a through the periphery of the drug-containing body 1a and heat generation. From the gap between the body 12 and the heat conductive member 3a, through the central hole 15 in the tubular body 16, the evaporation port 10
A heat rising airflow toward a is also generated, and the evaporation and diffusion of the drug can be performed more smoothly.
【0027】図3は、小型のブロック状発熱体を用いた
場合の構成例である。この構成例においては、塊状の薬
剤含有体1bが用いられ、また容器2bは、上面中央部
に上記薬剤含有体1bを載置するための凹部18が形成
された底板部3bと該底板部3bに被冠された半球状の
キャップ部17とからなり、これら底板部3b及びキャ
ップ部17はいずれも熱伝導性部材から作製されてい
る。また、底板部3bの周縁は複数箇所切り欠かれて通
気口8bが形成され、またその下面中央部から筒体19
が垂下され、該筒体19内にブロック状発熱体12bが
配設される。従って、図3に示す構成の場合、塊状の薬
剤含有体1bはそのほぼ全周面が熱伝導性部材の容器2
bにより加熱され、より均一な加熱が行われると共に、
保温効果にも優れている。FIG. 3 shows an example of the configuration when a small block-shaped heating element is used. In this configuration example, a lumpy drug-containing body 1b is used, and the container 2b has a bottom plate portion 3b and a bottom plate portion 3b each having a concave portion 18 for mounting the drug-containing body 1b in the center of the upper surface. And a cap portion 17 having a hemispherical shape that is capped on the bottom plate portion 3b and the cap portion 17 are both made of a heat conductive member. Further, the peripheral edge of the bottom plate portion 3b is cut out at a plurality of positions to form the vent hole 8b, and the cylindrical body 19 is formed from the center portion of the lower surface thereof.
And the block-shaped heating element 12b is disposed inside the cylindrical body 19. Therefore, in the case of the configuration shown in FIG. 3, the bulk drug-containing body 1b has a container 2 whose substantially entire circumferential surface is a heat conductive member.
It is heated by b, and more uniform heating is performed, and
It also has an excellent heat retention effect.
【0028】図4は、環状あるいは半環状の放熱部を有
する発熱体を具備した加熱蒸散装置に装着した例であ
る。この構成例においては、熱伝導性部材3cは上部2
0が漏斗状で下部21が筒状に形成されており、漏斗状
部20と筒状部21の接続部内周面には複数個の突部2
2が突設され、該突部22に薬剤含有体1cが載置され
るように構成されている。一方、容器2cは、底部に上
記筒状部21を挿入し得る大きさの中央孔23が形成さ
れた容器状の保護部材9cからなり、該保護部材9cは
係合段部7cにおいて上下に2分割できる構造となって
いる。上記熱伝導性部材3cの漏斗状部20は容器2c
内に収容され、一方、その下方の筒状部21の周囲には
リング状の発熱体12cが配設される。図4に示す構成
の場合、発熱体12cからの熱が熱伝導性部材3cに伝
達されると、薬剤含有体1cはその周囲の漏斗状部20
から均一に加熱され、また、容器内部の温度上昇に伴
い、図中矢印で示すように、加熱蒸散装置11cの底部
中央に形成された通気口24から熱伝導性部材3cの筒
状部21を経て薬剤含有体1cの周囲を通り容器2c上
部の蒸散口10cに向かう熱上昇気流が発生し、薬剤含
有体1cから蒸散した薬剤は上記熱上昇気流に乗ってス
ムーズに蒸散口10cより拡散する。この場合にも、保
護部材9cからなる容器2cは、薬剤含有体1cを保護
していると共に、加熱時の保温材料としても機能してい
る。このため、容器自体は高い保温性をもち、一度蒸散
した薬剤が蒸散口10c周辺に付着することを防止す
る。FIG. 4 shows an example of mounting on a heating evaporation device equipped with a heating element having an annular or semi-annular radiator. In this configuration example, the heat conductive member 3c has the upper portion 2
0 is a funnel shape and the lower part 21 is formed in a cylindrical shape, and a plurality of protrusions 2 are formed on the inner peripheral surface of the connecting portion of the funnel shape part 20 and the cylindrical part 21.
2 is provided so as to project, and the drug-containing body 1c is mounted on the projecting portion 22. On the other hand, the container 2c is composed of a container-shaped protection member 9c having a central hole 23 having a size into which the cylindrical portion 21 can be inserted, and the protection member 9c is vertically arranged at the engagement step 7c. It has a structure that can be divided. The funnel-shaped portion 20 of the heat conductive member 3c is the container 2c.
On the other hand, a ring-shaped heating element 12c is arranged around the cylindrical portion 21 below the inside. In the case of the configuration shown in FIG. 4, when the heat from the heating element 12c is transferred to the heat conductive member 3c, the drug-containing body 1c has a funnel-shaped portion 20 around it.
Is heated uniformly, and as the temperature inside the container rises, as shown by the arrow in the figure, the cylindrical portion 21 of the heat conductive member 3c is removed from the vent hole 24 formed in the center of the bottom of the heating evaporation device 11c. A heat rising airflow that passes through the periphery of the drug containing body 1c toward the evaporation port 10c in the upper part of the container 2c is generated, and the drug evaporated from the drug containing body 1c rides on the heat rising airflow and smoothly diffuses from the evaporation port 10c. Also in this case, the container 2c including the protection member 9c protects the drug-containing body 1c and also functions as a heat retaining material during heating. Therefore, the container itself has a high heat retaining property and prevents the once evaporated drug from adhering to the periphery of the evaporation port 10c.
【0029】図5及び図6は、ヒーター偏心型リング状
放熱部を有する発熱体を用い、また熱伝導性部材が可動
式の2つ割り構造となっている例を示す。すなわち、熱
伝導性部材3dは、縦割りに2分割された各分割セグメ
ント25a,25bにより全体として上部小径部と下部
大径部を有する筒状体を構成する構造を有し、各分割セ
グメント25a,25bの上部分割端面は、上端面に向
って拡大する切欠部が形成されるように傾斜面26とさ
れている。また、各分割セグメント25a,25bの上
端部外側面にはテーパ27が付けられている。このよう
な可動式2分割構造の熱伝導性部材3dを発熱体12d
のリング状放熱筒28に装着するに際しては、両分割セ
グメント25a,25bの上端部外側面には挿入し易い
ようにテーパ27が付けられているので、発熱体12d
のリング状放熱筒28に容易に挿入することができる。
挿入時に分割セグメント25a,25bの上部小径部が
リング状放熱筒28の下端内周縁に摺接して、支点Sよ
りも上方において横方向からの力が加えられると分割セ
グメント25a,25bが内側に倒れ込むので、リング
状放熱筒28に容易に挿入される。さらに挿入を進める
と、分割セグメント25a,25bの上部小径部の下部
の拡開されている部分に、支点Sよりも下方において発
熱体下端周縁によって横方向からの力が加えられるの
で、正立した元の状態に戻り、両分割セグメント25
a,25bの上部小径部外面がリング状放熱筒28内面
に接触し、効率的な熱伝導が行われる。FIGS. 5 and 6 show an example in which a heating element having a heater eccentric ring-shaped heat radiation portion is used, and the heat conductive member has a movable split structure. That is, the heat conductive member 3d has a structure in which the divided segments 25a and 25b, which are vertically divided into two, constitute a tubular body having an upper small diameter portion and a lower large diameter portion as a whole. , 25b are formed as inclined surfaces 26 so that a cutout portion that expands toward the upper end surface is formed. A taper 27 is attached to the outer surface of the upper end of each of the divided segments 25a and 25b. The heat-conducting member 3d having such a movable two-division structure is attached to the heating element 12d.
When mounted on the ring-shaped heat radiation tube 28, the heating elements 12d are tapered because the outer surfaces of the upper ends of the two divided segments 25a and 25b are easily inserted.
It can be easily inserted into the ring-shaped heat dissipation cylinder 28.
At the time of insertion, the upper small diameter portions of the divided segments 25a and 25b slide on the inner peripheral edge of the lower end of the ring-shaped heat radiation cylinder 28, and when a lateral force is applied above the fulcrum S, the divided segments 25a and 25b fall inward. Therefore, it is easily inserted into the ring-shaped heat dissipation cylinder 28. When the insertion is further advanced, a lateral force is applied by the lower edge of the heating element below the fulcrum S to the widened portion of the lower portion of the upper small diameter portion of the divided segments 25a and 25b, so that the segment is upright. Return to the original state, both split segments 25
The outer surfaces of the upper small-diameter portions of a and 25b come into contact with the inner surface of the ring-shaped heat dissipation cylinder 28, and efficient heat conduction is performed.
【0030】なお、熱伝導性部材の分割セグメントの形
状によっては、各分割セグメントを単独で水平面に置い
た場合、分割セグメント自体の重心の位置によっては倒
れが生じるが、その重心が図7に示すように正立し又は
外方向(図中、中空矢印で示す)に倒れる位置にある場
合、発熱体のリング状放熱筒に挿入する際は前記と同様
にして内側に倒れ込むが、挿入後は重力によって最も安
定な位置で止まり、結果的に分割セグメント25a′
(他方の分割セグメントは図示省略)の上部小径部外面
は発熱体のリング状放熱筒内面に接触する(重心が外方
向に倒れる位置にあっても、容器2dによって維持でき
る)。また、両分割セグメント25a,25bの中央部
をピン等の適当な連結手段(図示せず)により枢動自在
に連結し、またバネ等適当な付勢手段(図示せず)によ
り両分割セグメント25a,25bの上部小径部が拡開
するように付勢されるような構成とすることもできる。
このような可動式2分割構造の熱伝導性部材の場合に
も、両分割セグメント25a,25bの上端部外側面に
テーパ27が付けられているので、拡開させようとする
方向の付勢力に抗して容易にリング状放熱筒28内に押
し込むことができ、一旦装着した後は、弾性付勢力によ
り熱伝導性部材3dの両分割セグメント25a,25b
の上部小径部が拡開する方向に付勢され、発熱体12d
のリング状放熱筒28内面に圧接され、より効率的な熱
伝導が可能となる。Note that depending on the shape of the divided segments of the heat conductive member, when each divided segment is placed alone on a horizontal plane, tilting occurs depending on the position of the center of gravity of the divided segment itself, but the center of gravity is shown in FIG. When it is in the upright position or is tilted outward (indicated by the hollow arrow in the figure), it is tilted inward when it is inserted into the ring-shaped heat radiation tube of the heating element in the same manner as described above, but gravity after insertion. Stops at the most stable position, resulting in the segment 25a '
The outer surface of the upper small-diameter portion of the other segment (not shown) comes into contact with the inner surface of the ring-shaped heat radiating cylinder of the heating element (even if the center of gravity is tilted outward, it can be maintained by the container 2d). Further, the central portions of the two divided segments 25a and 25b are pivotally connected by a suitable connecting means (not shown) such as a pin, and the both divided segments 25a are connected by a suitable biasing means (not shown) such as a spring. , 25b, the upper small diameter portion may be urged to expand.
Also in the case of such a thermally conductive member having a movable two-divided structure, since the outer surfaces of the upper ends of the two divided segments 25a and 25b are provided with the taper 27, the biasing force in the direction of expanding the two is increased. It can be easily pushed into the ring-shaped heat dissipation cylinder 28 against resistance, and once mounted, it is elastically biased to both the divided segments 25a, 25b of the heat conductive member 3d.
The upper small diameter portion of the heating element is urged in the expanding direction, and the heating element 12d
It is pressed against the inner surface of the ring-shaped heat radiating cylinder 28 to enable more efficient heat conduction.
【0031】一方、容器2dは、底板29中央に内側に
向かって突出する筒状部30が形成された容器状の保護
部材9dからなり、該保護部材9dは係合段部7dにお
いて上下に2分割できる構造となっている。容器2d内
には、上記筒状部30上端面に薬剤含有体1dが載置さ
れ、また該薬剤含有体1dを包囲するように前記可動式
2分割構造の熱伝導性部材3dが収納される。また、容
器2dの上記筒状部30内には、薬剤の蒸散終了に合わ
せて機能し、薬剤蒸散終了を知らせるインジケーター機
能を有するインジケーター機能部材31が嵌合されてい
る。このようなインジケーター機能部材31としては、
加熱により色調変化を生ずる種々の材料を用いることが
できる。例えば、加熱により経時的に色調変化を呈する
電子供与性呈色性有機化合物や、蒸発又は昇華して色調
変化を生じさせる色素を含有した材料や昇華剤等を用い
ることができる。また、アントラキノン系油溶性染料、
モノアゾ系油溶性染料、ジスアゾ系油性染料、トリアリ
ルメタン系油性染料、ナフタルイミド系油性染料、アン
トラキノン系分散染料、塩基性染料などの加熱により経
時的に高分子物質中を移行する移行性染料を含有する材
料を用い、容器2dの底板29に合成樹脂を用い、加熱
により上記移行性染料が容器2dの底板29に経時的に
移行し、該底板29の色調変化によってインジケーター
機能を発揮させるように構成することもできる。上記の
ように内部に薬剤含有体1d及び可動式2分割構造の熱
伝導性部材3dが収納された容器2dは、ドーム状の加
熱蒸散装置32の中板部33に形成された内向凹陥部内
に装着され、また、前記したように熱伝導性部材3dの
上部小径部は発熱体12dのリング状放熱筒28内に装
着される。容器2dと加熱蒸散装置32の中板部33の
装着方法は、螺合、スナップ嵌め等任意の方法が採用で
きる。On the other hand, the container 2d is composed of a container-shaped protection member 9d having a tubular portion 30 projecting inwardly at the center of the bottom plate 29, and the protection member 9d is vertically arranged at the engagement step portion 7d. It has a structure that can be divided. In the container 2d, the drug-containing body 1d is placed on the upper end surface of the tubular portion 30, and the heat conductive member 3d having the movable two-division structure is housed so as to surround the drug-containing body 1d. . Further, an indicator function member 31 is fitted in the cylindrical portion 30 of the container 2d, the indicator function member 31 having an indicator function that functions in accordance with the end of the evaporation of the drug and notifies the end of the evaporation of the drug. As such an indicator function member 31,
Various materials that change the color tone by heating can be used. For example, an electron-donating color-developing organic compound that exhibits a color tone change over time with heating, a material containing a dye that causes a color tone change by evaporation or sublimation, a sublimation agent, and the like can be used. Also, anthraquinone oil-soluble dyes,
Transferring dyes such as monoazo-based oil-soluble dyes, disazo-based oil-based dyes, triallylmethane-based oil-based dyes, naphthalimide-based oil-based dyes, anthraquinone-based disperse dyes, and basic dyes that migrate in polymeric substances over time with heating Using a material contained therein, a synthetic resin is used for the bottom plate 29 of the container 2d, and the transferable dye is transferred to the bottom plate 29 of the container 2d with heating with time, and the indicator function is exhibited by the color tone change of the bottom plate 29. It can also be configured. As described above, the container 2d in which the drug-containing body 1d and the thermally conductive member 3d having the movable two-divided structure are housed is placed in the inward recessed portion formed in the middle plate portion 33 of the dome-shaped heating evaporation device 32. The upper small diameter portion of the heat conductive member 3d is mounted in the ring-shaped heat radiation cylinder 28 of the heating element 12d as described above. As a method of mounting the container 2d and the middle plate portion 33 of the heating evaporation device 32, any method such as screwing or snap fitting can be adopted.
【0032】図5及び図6に示す構成の場合、発熱体1
2dの発熱によって容器2dの内部温度が上昇するに伴
い、図中矢印で示すように、容器2dの底板29に形成
された通気口8dから薬剤含有体1d周辺を経て蒸散口
10dに向かう熱上昇気流が発生すると共に、加熱蒸散
装置32の周壁底部に形成された通気口34から中板部
33に形成された通気口35を経て蒸散口10dに向か
う熱上昇気流も発生し、薬剤の蒸散・拡散をよりスムー
ズに行うことができると共に、薬剤含有体1dはそのほ
ぼ全周面が熱伝導性部材3dにより加熱され、より均一
な加熱が行われると共に、これらは保護部材9dから成
る容器2d内に収容されているので保温効果にも優れて
いる。また、薬剤蒸散の経過に伴い、前記インジケータ
ー機能部材31により使用経過時間、終点あるいは使用
期間超過を表示することができる。さらに、前記構成例
のように可動式2分割構造の熱伝導性部材を用いること
により、加熱蒸散装置(発熱体)への装着性向上、熱伝
導効率向上といった利点が得られる。特に図6に示した
ようなリング状放熱筒に熱伝導性部材を挿入するような
場合、熱伝導性部材が単一部材の場合、又は複数部材で
も固定式のときは、その装着性からリング状放熱筒より
も小さい径で熱伝導性部材を構成する必要があり、発熱
体と熱伝導性部材を密に接触させることは困難である。
これに対し、熱伝導性部材を図5及び図6に示すような
可動式の分割構造とすることにより、装着性が向上する
と共に、所定位置に熱伝導性部材が可動してリング状放
熱筒に接触し、あるいはまた各分割セグメントをバネ手
段等を介して連結した場合には、装着終了時に発熱体に
向って熱伝導性部材の一部が付勢され、圧接される。当
然のことながら、発熱体と熱伝導性部材との間に空隙を
介在させるよりも、直接接触させることにより、熱伝導
効率は向上する。In the case of the configuration shown in FIGS. 5 and 6, the heating element 1
As the internal temperature of the container 2d rises due to the heat generated by 2d, the heat rises from the vent hole 8d formed in the bottom plate 29 of the container 2d to the evaporation port 10d through the periphery of the drug-containing body 1d as shown by the arrow in the figure. An airflow is generated, and a heat rising airflow is also generated from the ventilation hole 34 formed in the bottom portion of the peripheral wall of the heating evaporation device 32 to the evaporation hole 10d through the ventilation hole 35 formed in the middle plate part 33. In addition to being able to diffuse more smoothly, the drug-containing body 1d is heated almost uniformly on its entire peripheral surface by the heat conductive member 3d to perform more uniform heating, and these are contained in the container 2d composed of the protection member 9d. Since it is housed in, it has an excellent heat retention effect. Further, the elapsed time of use, the end point, or the expiration of the use period can be displayed by the indicator function member 31 with the progress of the evaporation of the drug. Further, by using the heat conductive member having the movable two-divided structure as in the above-mentioned configuration example, advantages such as improvement of the attachment property to the heating evaporation device (heating element) and improvement of heat conduction efficiency can be obtained. In particular, when the heat conductive member is inserted into the ring-shaped heat dissipation tube as shown in FIG. 6, when the heat conductive member is a single member, or when a plurality of members are fixed, the ring can be attached due to their mountability. It is necessary to configure the heat conductive member with a diameter smaller than that of the heat dissipation tube, and it is difficult to closely contact the heat generating member and the heat conductive member.
On the other hand, by adopting a movable split structure as shown in FIG. 5 and FIG. 6, the heat conductive member is improved in mountability, and the heat conductive member is moved to a predetermined position so that the ring-shaped heat dissipation tube is moved. , Or when the divided segments are connected to each other via spring means or the like, a part of the heat conductive member is urged toward the heat generating element at the end of the attachment and is pressed against the heat generating element. As a matter of course, the heat conduction efficiency is improved by directly contacting the heat generating member and the heat conductive member, rather than by interposing the space therebetween.
【0033】図8は、円柱状の薬剤含有体と円筒状の熱
伝導性部材を用いた例を示す。すなわち、熱伝導性部材
3eは上下端が開口された円筒状に形成され、その下端
内周面には複数の突状係止部36が突設され、円柱状の
薬剤含有体1eは該突状係止部36により支持された状
態で円筒状熱伝導性部材3e内に配置される。また、円
筒状熱伝導性部材3eは、キヤップ状の保護部材9eの
上部中央に形成された係合部37の孔に嵌合される。キ
ャップ状保護部材9eの上部外周面には円周方向に沿っ
て断続的に所定長さの複数の突部38及び溝部39が形
成され、同様に、加熱蒸散装置40の下部器体41の容
器収納部42の下端部内周面にも同様な突部43及び溝
部(図示せず)が形成されている。薬剤含有体1eを収
容する円筒状熱伝導性部材3eが嵌合されたキャップ状
保護部材9eを加熱蒸散装置40に組み込むに当って
は、まず、キャップ状保護部材9eの上部外周面に形成
された突部38及び溝部39の切欠かれている部分を下
部器体41の容器収納部42の下端部内周面に形成され
た突部43に整合して、下方から挿入する。次いで、容
器収納部42の上面に突設された複数の台座部44に載
置された環状発熱体12e内に円筒状熱伝導性部材3e
の上端部が挿入された状態で、キャップ状保護部材9e
を若干回転させると、キャップ状保護部材9eと容器収
納部42のそれぞれの突部と溝部が嵌合し、装着される
と共に、それぞれの突部と溝部の間の切欠き部によって
キャップ状保護部材9eと容器収納部42との間に通気
口46が形成される。FIG. 8 shows an example in which a cylindrical drug-containing body and a cylindrical heat conductive member are used. That is, the heat conductive member 3e is formed in a cylindrical shape with upper and lower ends opened, and a plurality of projecting locking portions 36 are projectingly provided on the inner peripheral surface of the lower end thereof, so that the cylindrical drug-containing body 1e is projected. It is arranged in the cylindrical heat conductive member 3e in a state of being supported by the cylindrical locking portion 36. Further, the cylindrical heat conductive member 3e is fitted into the hole of the engaging portion 37 formed at the center of the upper portion of the cap-shaped protection member 9e. A plurality of projections 38 and grooves 39 having a predetermined length are intermittently formed along the circumferential direction on the upper outer peripheral surface of the cap-shaped protection member 9e. Similarly, the container of the lower vessel 41 of the heating evaporation device 40 is formed. Similar protrusions 43 and grooves (not shown) are also formed on the inner peripheral surface of the lower end portion of the storage portion 42. In assembling the cap-shaped protection member 9e fitted with the cylindrical heat-conductive member 3e for accommodating the drug-containing body 1e into the heat evaporation device 40, first, the cap-shaped protection member 9e is formed on the upper outer peripheral surface of the cap-shaped protection member 9e. The notched portions of the protruding portion 38 and the groove portion 39 are aligned with the protruding portion 43 formed on the inner peripheral surface of the lower end portion of the container accommodating portion 42 of the lower body 41, and are inserted from below. Next, the cylindrical heat conductive member 3e is placed in the annular heating element 12e placed on the plurality of pedestal portions 44 projectingly provided on the upper surface of the container housing portion 42.
With the upper end of the cap inserted, the cap-shaped protection member 9e
When the cap-shaped protection member 9e and the container housing portion 42 are fitted and fitted with each other by slightly rotating the cap-shaped protection member 9e, the cap-shaped protection member is formed by the notches between the projections and the groove portions. A ventilation hole 46 is formed between 9e and the container storage 42.
【0034】図8に示す構成の場合、発熱体12eの発
熱によって内部温度が上昇するに伴い、図中矢印で示す
ように、加熱蒸散装置40の下部器体41の下部に形成
された通気口48から薬剤含有体1eと円筒状熱伝導性
部材3eとの間の空隙部を経て上部器体45の頂面中央
部に形成された蒸散口10eに向かう熱上昇気流が発生
すると共に、通気口46及び47から発熱体12eと熱
伝導性部材3eとの空隙部を経て蒸散口10eに向かう
熱上昇気流及び通気口49から発熱体12e周辺を経て
蒸散口10eに向かう熱上昇気流も発生し、薬剤の蒸散
・拡散をよりスムーズに行うことができる。また、円柱
状の薬剤含有体1eはその全周面が円筒状熱伝導性部材
3eにより加熱されるので、より均一な加熱が行われる
と共に、保温効果にも優れている。以上説明した構成例
は、本発明の加熱蒸散方法の幾つかの具体例であって、
本発明がこれらに限定されるものでないことはもとより
であり、各種加熱蒸散装置、薬剤含有体及び容器の構
造、構成は任意であり、各種形態のものを利用できる。In the case of the structure shown in FIG. 8, as the internal temperature rises due to the heat generated by the heating element 12e, the vent hole formed in the lower part of the lower body 41 of the heating evaporation device 40 as shown by the arrow in the drawing. A heat rising airflow is generated from 48 toward the transpiration port 10e formed in the central portion of the top surface of the upper body 45 through the gap between the drug-containing body 1e and the cylindrical heat conductive member 3e, and the vent hole is also generated. A heat rising airflow from 46 and 47 through the gap between the heating element 12e and the heat conductive member 3e toward the transpiration port 10e and a heat rising airflow from the vent 49 through the periphery of the heating element 12e to the transpiration port 10e are also generated. The chemicals can be evaporated and diffused more smoothly. In addition, since the cylindrical drug-containing body 1e is heated by the cylindrical heat conductive member 3e on the entire peripheral surface thereof, more uniform heating is performed and the heat retaining effect is excellent. The configuration examples described above are some specific examples of the heating evaporation method of the present invention,
It goes without saying that the present invention is not limited to these, and the structures and configurations of various heating evaporation devices, drug-containing bodies and containers are arbitrary, and various forms can be used.
【0035】[0035]
【実施例】以下、実施例及び比較例を示して、本発明に
ついてさらに具体的に説明する。 実施例1 市販の加熱蒸散装置の正特性サーミスターを用いた板状
発熱体上に、耐熱性プラスチック板(ポリフェニルサル
ホン製)、銅板及びアルミニウム板の各板(各々24×
36mm、厚み1mm)をそれぞれ載置し、各板上面の
表面温度を熱電対型表面温度計にて測定した。また、発
熱体表面温度についても同様に測定した。尚、温度測定
部は、各板又は発熱体の対角線を6等分する5点(図9
参照)とし、室温25℃の条件で測定した。測定結果を
表1及び図10に示す。EXAMPLES The present invention will be described more specifically below with reference to Examples and Comparative Examples. Example 1 Each of a heat-resistant plastic plate (made of polyphenylsulfone), a copper plate, and an aluminum plate (24 × each) was placed on a plate-shaped heating element using a positive temperature coefficient thermistor of a commercially available heating evaporation device.
36 mm, thickness 1 mm) was placed on each plate, and the surface temperature of the upper surface of each plate was measured with a thermocouple type surface thermometer. The surface temperature of the heating element was also measured in the same manner. In addition, the temperature measuring unit has five points (see FIG. 9) that divide the diagonal line of each plate or heating element into six equal parts.
Measurement) under the condition of room temperature of 25 ° C. The measurement results are shown in Table 1 and FIG.
【0036】[0036]
【表1】 [Table 1]
【0037】実施例2 市販の加熱蒸散装置の正特性サーミスターを用いた板状
発熱体50上に、耐熱性プラスチック板(ポリフェニレ
ンエーテル製)、銅板及びアルミニウム板の各板51
(各々60×36mm、厚み1mm)をそれぞれ図11
に示すように設置し、更に各板51の発熱体50と逆側
の上面に市販の蚊取用マット52を載置し、加熱蒸散を
行い、3時間毎に揮散した殺虫有効成分を吸引してシリ
カゲルに補集し、これを12時間目まで繰り返し、各々
についてアセトンを用いて抽出した試料溶液をガスクロ
マトグラフィーによって定量分析した。次に、12時間
加熱蒸散後の薬剤含有体をアセトンを用いて抽出し、同
様に有効成分の定量分析を行った。尚、殺虫有効成分と
してはd・d−T80−プラレトリンを用いた。各々の
結果を表2に示す。Example 2 A heat-resistant plastic plate (made of polyphenylene ether), a copper plate, and an aluminum plate 51 were placed on a plate-shaped heating element 50 using a positive temperature coefficient thermistor of a commercially available heating evaporation device.
(60 × 36 mm each, thickness 1 mm) is shown in FIG.
Installed as shown in Fig. 1, and further placing a commercially available mosquito repellent mat 52 on the upper surface of each plate 51 opposite to the heating element 50, heat vaporization is performed, and the voluntary insecticidal active ingredient is sucked every 3 hours. And collected on silica gel and repeated for 12 hours, and a sample solution extracted with acetone for each was quantitatively analyzed by gas chromatography. Next, the drug-containing body after heat evaporation for 12 hours was extracted with acetone, and the active ingredient was quantitatively analyzed in the same manner. In addition, d.d-T80-praletrin was used as the insecticidal active ingredient. The results of each are shown in Table 2.
【表2】 [Table 2]
【0038】表1及び図10に示す結果から明らかなよ
うに、発熱体上面の温度分布は、発熱体中心部が最も高
く、端へいくにしたがって温度は低くなる。発熱体上面
の最高温度と最低温度の温度差は、約40℃以上であ
る。比較的熱伝導度の低いポリフェニルサルホン製の板
を発熱体上に載置した場合の板上温度は、発熱体表面温
度よりも全体的に低くなり、最高温度と最低温度の温度
差も多少緩和されているが、更に温度差をなくすために
はかなりの厚みが必要と考えられ、熱損失が大きくな
り、市販の蚊取りマットの薬剤を蒸散させる場合には不
適当であった。しかし、熱伝導性の良好な銅板、アルミ
ニウム板(厚み1mm)の場合、温度差は緩和され、ほ
ぼ均一な温度分布を得た。更に、その温度も全体的に低
下しておらず、発熱体表面の最高温度部に位置する部分
の温度を低下させ、温度の低い部分の温度を上昇させ
て、全体的に均一な温度となっている。このため、熱量
的には、市販の蚊取りマットの薬剤を蒸散させるには充
分であり、熱伝導性部材を発熱体上面に設置することに
より、薬剤含有体を均一に加熱でき、かつ、熱損失も非
常に少なく、薬剤を蒸散させる上で非常に有効である。As is clear from the results shown in Table 1 and FIG. 10, the temperature distribution on the upper surface of the heating element is highest at the central portion of the heating element and lowers toward the ends. The temperature difference between the maximum temperature and the minimum temperature of the upper surface of the heating element is about 40 ° C. or higher. When a plate made of polyphenylsulfone, which has a relatively low thermal conductivity, is placed on the heating element, the on-board temperature is generally lower than the heating element surface temperature, and the temperature difference between the maximum temperature and the minimum temperature is also Although it was somewhat relaxed, it was thought that a considerable thickness was required to eliminate the temperature difference, heat loss was large, and it was unsuitable for evaporating the chemicals of a commercially available mosquito repellent mat. However, in the case of a copper plate and an aluminum plate (thickness 1 mm) having good thermal conductivity, the temperature difference was alleviated and a substantially uniform temperature distribution was obtained. Furthermore, the temperature is not entirely lowered, and the temperature of the portion located at the highest temperature portion of the heating element surface is lowered, and the temperature of the low temperature portion is raised, resulting in an overall uniform temperature. ing. Therefore, the amount of heat is sufficient to evaporate the drug on the commercially available mosquito repellent mat, and by installing the heat conductive member on the upper surface of the heating element, the drug-containing body can be uniformly heated and the heat loss is reduced. It is also very effective in evaporating the drug.
【0039】次に、表2に示す結果から明らかなよう
に、熱伝導性部材を先の実施例1よりも大きくし、発熱
体板上からはなれた位置で薬剤(d・d−T80−プラ
レトリン)を蒸散させた場合、ポリフェニレンエーテル
製の板では、いかなる時間においても薬剤の蒸散は得ら
れず、発熱体からの熱が有効に利用されていない。これ
に対して、熱伝導度の高い部材(銅板、アルミニウム
板)を用いた場合、所期の有効な薬剤蒸散が得られた。
更に、発熱体上に直に蚊取りマットを載置した場合に比
べ、使用後半での薬剤蒸散量の低下が抑えられ、比較的
長時間に亘って薬剤蒸散量が維持される傾向が見られる
と共に、薬剤の推定未回収率も少なかった。これは、加
熱面の温度分布が均一であり、局所加熱を受けないた
め、薬剤の分解が抑えられたためと推定される。しか
も、熱伝導性部材を用いることで、発熱体の形状や、場
所にとらわれず、任意の場所で薬剤を蒸散させることが
可能になる。Next, as is clear from the results shown in Table 2, the heat conductive member was made larger than in the first embodiment, and the drug (d.d-T80-praletrin) was placed at a position apart from the heating element plate. 2) is evaporated, the plate made of polyphenylene ether does not evaporate the drug at any time, and the heat from the heating element is not effectively used. On the other hand, when a member with high thermal conductivity (copper plate, aluminum plate) was used, the desired effective chemical evaporation was obtained.
Furthermore, compared with the case where the mosquito repellent mat is placed directly on the heating element, the decrease in the amount of drug evaporated in the latter half of use is suppressed, and the amount of drug evaporated tends to be maintained for a relatively long time. The estimated unrecovered rate of the drug was also low. It is presumed that this is because the temperature distribution on the heating surface was uniform and the heating surface was not subjected to local heating, so that the decomposition of the drug was suppressed. Moreover, by using the heat conductive member, it is possible to evaporate the drug at any place regardless of the shape and the place of the heating element.
【0040】実施例3 図8に示す構成の薬剤蒸散装置において、無水リン酸水
素カルシウム(89.8w/w%)、ナイロン12
(5.0w/w%)、結晶セルロース(4.0w/w
%)、ステアリン酸マグネシウム(1.0w/w%)、
ステアリル−β−(3,5−ジ−t−ブチル−4−ヒド
ロキシフェニル)プロピオネート(0.2w/w%)か
らなる基材に、加熱蒸散性殺虫剤(d・d−T80−プ
ラレトリン)310mgを浸漬により含有させてなる円
柱状薬剤含有体1eを用い、これを、円筒状熱伝導性部
材3e内に配置した状態でキャップ状保護部材9eに嵌
合し、円筒状熱伝導性部材3eの上端部をリング状発熱
体12e内に配置して加熱し、殺虫剤を蒸散させた。Example 3 An anhydrous calcium hydrogen phosphate (89.8 w / w%), nylon 12 was used in the chemical vaporization apparatus having the structure shown in FIG.
(5.0 w / w%), crystalline cellulose (4.0 w / w
%), Magnesium stearate (1.0 w / w%),
On a substrate consisting of stearyl-β- (3,5-di-t-butyl-4-hydroxyphenyl) propionate (0.2 w / w%), a heat transpiration insecticide (d · d-T80-praletrin) 310 mg A cylindrical drug-containing body 1e in which is contained by dipping is fitted into the cap-shaped protection member 9e in a state of being arranged in the cylindrical heat-conductive member 3e, and The upper end portion was placed in the ring-shaped heating element 12e and heated to evaporate the insecticide.
【0041】比較例1 図12に示すように、上記実施例3と同じ基材の円柱状
薬剤含有体1eを用い、これを円筒状熱伝導性部材を用
いないでキャップ状保護部材9fに嵌合し、薬剤含有体
1eの上端部をリング状発熱体12eにより加熱し、殺
虫剤を蒸散させた。試験は、発熱体12eに通電後、各
加熱時間目の薬剤蒸散量を前記実施例2と同様の方法で
定量分析し、測定した。その結果を表3に示す。Comparative Example 1 As shown in FIG. 12, a cylindrical drug-containing body 1e having the same base material as in Example 3 was used, and this was fitted to a cap-shaped protection member 9f without using a cylindrical heat conductive member. Then, the upper end of the drug-containing body 1e was heated by the ring-shaped heating element 12e to evaporate the insecticide. In the test, after the heating element 12e was energized, the amount of chemical vaporization at each heating time was quantitatively analyzed and measured in the same manner as in Example 2. The results are shown in Table 3.
【表3】 [Table 3]
【0042】表3に示す結果より、図8に示すように熱
伝導性部材を用いて薬剤含有体を加熱した実施例3の場
合、360時間に亘って安定して薬剤が蒸散したが、熱
伝導性部材を用いなかった比較例1においては、長期間
に亘る安定蒸散は得られなかった。これは、図8に示す
構成においては、比較的均一な温度で薬剤含有体が加熱
されるために、経時的な薬剤の劣化を生じにくく、被加
熱面積も広く、薬剤含有体内部での薬剤の移行距離も少
なくてすむため、長期間の使用に耐えられる。これに対
し、図12に示す構成では、発熱体による局部加熱のた
め、薬剤含有体上部において、経時的な薬剤の分解を生
じ、薬剤含有体の被加熱部において目詰まり現象を生
じ、更には、薬剤含有体下方に含まれる薬剤が上方の蒸
散部分まで移行できずに封じこまれたままになったため
と推定される。このように、発熱体の形状に合わせた熱
伝導性部材を介在して薬剤含有体を加熱することによ
り、長期間に亘って、安定に、しかも薬剤を有効に蒸散
させることが可能になる。また、使用する薬剤に応じ
て、熱伝導度の異なる熱伝導性部材を用いることによ
り、発熱体温度に限定されずに各種薬剤を蒸散させるこ
とも可能になる。From the results shown in Table 3, in the case of Example 3 in which the drug-containing body was heated using the heat conductive member as shown in FIG. 8, the drug was stably evaporated over 360 hours. In Comparative Example 1 in which the conductive member was not used, stable transpiration was not obtained over a long period of time. This is because in the configuration shown in FIG. 8, since the drug-containing body is heated at a relatively uniform temperature, deterioration of the drug over time does not easily occur, the heated area is wide, and the drug inside the drug-containing body is large. It can be used for a long period of time because it requires a small transition distance. On the other hand, in the configuration shown in FIG. 12, the local heating by the heating element causes the decomposition of the drug over time in the upper part of the drug-containing body, and the clogging phenomenon occurs in the heated part of the drug-containing body. It is presumed that the drug contained in the lower part of the drug-containing body could not be transferred to the transpiration part in the upper part and remained contained. As described above, by heating the drug-containing body via the heat conductive member that matches the shape of the heating element, it becomes possible to stably and effectively evaporate the drug over a long period of time. Further, by using a heat conductive member having a different heat conductivity depending on the drug to be used, it is possible to evaporate various drugs without being limited to the temperature of the heating element.
【図1】本発明の薬剤の加熱蒸散方法の一形態の構成例
を示す概略断面図である。FIG. 1 is a schematic cross-sectional view showing a structural example of one mode of the method for heating and evaporating a drug of the present invention.
【図2】本発明の他の構成例の要部を示す概略断面図で
ある。FIG. 2 is a schematic cross-sectional view showing a main part of another configuration example of the present invention.
【図3】本発明のさらに他の構成例の要部を示す概略断
面図である。FIG. 3 is a schematic cross-sectional view showing a main part of still another configuration example of the present invention.
【図4】本発明の薬剤の加熱蒸散方法の他の形態の構成
例を示す概略断面図である。FIG. 4 is a schematic cross-sectional view showing a structural example of another embodiment of the method for heating and evaporating a drug of the present invention.
【図5】本発明の薬剤の加熱蒸散方法のさらに他の形態
の構成例を示す概略断面図である。FIG. 5 is a schematic cross-sectional view showing a structural example of still another embodiment of the method for heating and evaporating a drug of the present invention.
【図6】図5に示す構成例の要部概略断面図である。6 is a schematic cross-sectional view of a main part of the configuration example shown in FIG.
【図7】熱伝導性部材の分割セグメントの他の形状例を
示す概略断面図である。FIG. 7 is a schematic cross-sectional view showing another example of the shape of divided segments of the heat conductive member.
【図8】本発明の薬剤の加熱蒸散方法のさらに別の形態
の構成例を示す概略断面図である。FIG. 8 is a schematic cross-sectional view showing a structural example of still another mode of the method for heating and evaporating a drug of the present invention.
【図9】実施例1で用いた各板の温度測定部を示す平面
図である。FIG. 9 is a plan view showing a temperature measuring unit of each plate used in Example 1;
【図10】実施例1で用いた各板の測定部と測定温度と
の関係を示すグラフである。FIG. 10 is a graph showing the relationship between the measurement unit of each plate used in Example 1 and the measurement temperature.
【図11】実施例2で用いた各板を介しての蚊取用マッ
トの加熱形態を示す斜視図である。FIG. 11 is a perspective view showing a heating form of a mosquito catching mat through each plate used in Example 2.
【図12】比較例1で用いた加熱蒸散装置の構成を示す
概略断面図である。FIG. 12 is a schematic cross-sectional view showing a configuration of a heating evaporation device used in Comparative Example 1.
1,1a,1b,1c,1d,1e 薬剤含有体、
2,2a,2b,2c,2d 容器、 3,3a,3
b,3c,3d,3e 熱伝導性部材、 4 台座部、
5,6 凸部、 8,8a,8b,8d,13,1
4,24,34,35,47,48,49 通気口、
9,9a,9c,9d,9e 保護部材、 10,10
a,10b,10c,10d,10e 蒸散口、 1
1,11c,32,40 加熱蒸散装置、 12,12
b,12c,12d,12e,50 発熱体、 25
a,25b,25a′ 分割セグメント、 28 リン
グ状放熱筒、31 インジケーター機能部材1, 1a, 1b, 1c, 1d, 1e drug-containing body,
2,2a, 2b, 2c, 2d container, 3,3a, 3
b, 3c, 3d, 3e heat conductive member, 4 pedestal part,
5, 6 convex part, 8, 8a, 8b, 8d, 13, 1
4,24,34,35,47,48,49 vents,
9, 9a, 9c, 9d, 9e Protective member, 10, 10
a, 10b, 10c, 10d, 10e transpiration port, 1
1, 11c, 32, 40 heating evaporation device, 12, 12
b, 12c, 12d, 12e, 50 heating element, 25
a, 25b, 25a 'divided segment, 28 ring-shaped heat dissipation tube, 31 indicator functional member
Claims (5)
り加熱するに際して、薬剤含有体と発熱体との間に熱伝
導性部材を発熱体に接触あるいは近接して設け、上記薬
剤含有体を熱伝導性部材を介在させて加熱し、薬剤を蒸
散させることを特徴とする薬剤の加熱蒸散方法。1. When heating a drug-containing body containing a drug with a heating element, a heat conductive member is provided between the drug-containing body and the heating element in contact with or in proximity to the heating element, and the drug-containing body is provided. A method for heating and evaporating a drug, which comprises heating by interposing a heat conductive member to evaporate the drug.
より薬剤含有体の周囲を概略囲繞し、加熱の際に薬剤含
有体の少なくとも一部の表面の周囲に下方及び/又は側
方より上方へ向かう熱上昇気流が生じるように上記熱伝
導性部材及び/又は保護部材内に連通する空間を形成し
たことを特徴とする請求項1に記載の加熱蒸散方法。2. A heat-conductive member and / or another protective member substantially surrounds the periphery of the drug-containing body, and at the time of heating, at least partially around the surface of the drug-containing body from below and / or from the side. The heating and evaporation method according to claim 1, wherein a space communicating with the heat conductive member and / or the protection member is formed so that an upward heat flow is generated.
薬剤蒸散口を設けたことを特徴とする請求項2に記載の
加熱蒸散方法。3. The heat evaporation method according to claim 2, wherein a drug evaporation port is provided at least at one position substantially above the drug containing body.
導性部材の各分割セグメントが可動であって、弾性付勢
力又は重力により発熱体に圧接又は接触されるようにし
たことを特徴とする請求項1乃至3のいずれか一項に記
載の加熱蒸散方法。4. A heat conductive member is formed in a divided body, and each divided segment of the heat conductive member is movable so as to be pressed into contact with or contact with a heating element by elastic biasing force or gravity. The heating evaporation method according to any one of claims 1 to 3.
たことを特徴とする請求項4に記載の加熱蒸散方法。5. The heat evaporation method according to claim 4, wherein the heat conductive member is formed in a vertically divided cylindrical body.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25628693A JP3422825B2 (en) | 1993-09-21 | 1993-09-21 | Heat evaporation of chemicals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25628693A JP3422825B2 (en) | 1993-09-21 | 1993-09-21 | Heat evaporation of chemicals |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0789806A true JPH0789806A (en) | 1995-04-04 |
JP3422825B2 JP3422825B2 (en) | 2003-06-30 |
Family
ID=17290547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP25628693A Expired - Fee Related JP3422825B2 (en) | 1993-09-21 | 1993-09-21 | Heat evaporation of chemicals |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3422825B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060254A1 (en) * | 2001-01-29 | 2002-08-08 | Fumakilla Limited | Chemical-containing formed material of type of heating of whole the material, container for holding chemical-containing formed material, device for heating and transpiring chemical and indicator for chemical to be heated and vaporized |
JP2002220304A (en) * | 2001-01-29 | 2002-08-09 | Fumakilla Ltd | Whole heating type drug-containing body, container for the same and heating apparatus for drug transpiration |
JP2002293703A (en) * | 2001-01-29 | 2002-10-09 | Fumakilla Ltd | Indicator for heat-evaporation agent |
JP2006517585A (en) * | 2003-01-30 | 2006-07-27 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Substrates for volatile material delivery systems |
JP2008048641A (en) * | 2006-08-23 | 2008-03-06 | Kobayashi Pharmaceut Co Ltd | Chemical-volatilizing device |
JP2009527253A (en) * | 2006-02-22 | 2009-07-30 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Air treatment apparatus having a heated volatile dispenser |
JP2010124723A (en) * | 2008-11-26 | 2010-06-10 | Earth Chem Corp Ltd | Thermal transpiration system and transpiration method using the same |
JP2011089769A (en) * | 2011-02-10 | 2011-05-06 | Mitsubishi Electric Corp | Water sterilization device and humidifier |
KR101053166B1 (en) * | 2011-03-02 | 2011-08-02 | (주)한성티앤아이 | Spraying nozzle pipe of freezing protection device for sprinkler of pesticide |
CN104012514A (en) * | 2014-06-17 | 2014-09-03 | 无锡商业职业技术学院 | Electric heating mosquito dispeller |
JP5894536B2 (en) * | 2010-12-02 | 2016-03-30 | 株式会社東芝 | Heating evaporator |
JP2023511867A (en) * | 2020-01-15 | 2023-03-23 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Dispenser with improved heater device |
-
1993
- 1993-09-21 JP JP25628693A patent/JP3422825B2/en not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7449154B2 (en) | 2001-01-29 | 2008-11-11 | Fumakilla Limited | Chemical-containing formed material of type of heating of whole the material, container for holding chemical-containing formed material, device for heating and transpiring chemical and indicator for chemical to be heated and vaporized |
JP2002220304A (en) * | 2001-01-29 | 2002-08-09 | Fumakilla Ltd | Whole heating type drug-containing body, container for the same and heating apparatus for drug transpiration |
JP2002293703A (en) * | 2001-01-29 | 2002-10-09 | Fumakilla Ltd | Indicator for heat-evaporation agent |
WO2002060254A1 (en) * | 2001-01-29 | 2002-08-08 | Fumakilla Limited | Chemical-containing formed material of type of heating of whole the material, container for holding chemical-containing formed material, device for heating and transpiring chemical and indicator for chemical to be heated and vaporized |
JP2006517585A (en) * | 2003-01-30 | 2006-07-27 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Substrates for volatile material delivery systems |
JP2009527253A (en) * | 2006-02-22 | 2009-07-30 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Air treatment apparatus having a heated volatile dispenser |
JP4928568B2 (en) * | 2006-02-22 | 2012-05-09 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Air treatment apparatus having a heated volatile dispenser |
JP2008048641A (en) * | 2006-08-23 | 2008-03-06 | Kobayashi Pharmaceut Co Ltd | Chemical-volatilizing device |
JP2010124723A (en) * | 2008-11-26 | 2010-06-10 | Earth Chem Corp Ltd | Thermal transpiration system and transpiration method using the same |
JP5894536B2 (en) * | 2010-12-02 | 2016-03-30 | 株式会社東芝 | Heating evaporator |
JP2011089769A (en) * | 2011-02-10 | 2011-05-06 | Mitsubishi Electric Corp | Water sterilization device and humidifier |
KR101053166B1 (en) * | 2011-03-02 | 2011-08-02 | (주)한성티앤아이 | Spraying nozzle pipe of freezing protection device for sprinkler of pesticide |
CN104012514A (en) * | 2014-06-17 | 2014-09-03 | 无锡商业职业技术学院 | Electric heating mosquito dispeller |
JP2023511867A (en) * | 2020-01-15 | 2023-03-23 | エス.シー. ジョンソン アンド サン、インコーポレイテッド | Dispenser with improved heater device |
Also Published As
Publication number | Publication date |
---|---|
JP3422825B2 (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3422825B2 (en) | Heat evaporation of chemicals | |
US5290546A (en) | Method for thermal vaporization of chemical | |
JP4499189B2 (en) | Controlled release of substances | |
US5891400A (en) | Volatile substance dispenser | |
TW537909B (en) | Wick based liquid emanation system | |
EP0362397B1 (en) | Heater-fumigator | |
US6478440B1 (en) | Night light air freshener | |
US20060078477A1 (en) | Methods and apparatus for a low-cost vapor-dispersing device | |
JP3308291B2 (en) | Heat-evaporation drug-containing body and method for heat-evaporation of drug using the same | |
BRPI0506896B1 (en) | volatile material-releasing substrates and methods for preparing them | |
JP3274730B2 (en) | Drug-containing substance for long-term heat evaporation and heat evaporation method of medicine using the same | |
JP3209601B2 (en) | Drug-containing substance for long-term heat evaporation and heat evaporation method of medicine using the same | |
JPH06284845A (en) | Unit for evaporating liquid medicine in heating and evaporating apparatus | |
JP3475296B2 (en) | Chemical evaporator for long-term transpiration | |
JP3275080B2 (en) | Heat evaporator for wicking heat evaporator | |
JP3475332B2 (en) | Chemical evaporator for long-term transpiration | |
JP2001086919A (en) | Liquid sucking wick of chemical fluid volatilizing container | |
JPS6070024A (en) | Liquefied gas type chemical agent heating and evaporating apparatus | |
JP5263588B2 (en) | Heating transpiration system and transpiration method using the same | |
JPH07322798A (en) | Heat-transpiring device for chemical | |
WO2003101499A1 (en) | Passive vapor-dispensing device | |
RU2140792C1 (en) | Transformerless device for evaporation of liquid when heating | |
JPH0517306A (en) | Process for thermal dissipation of agent | |
JP2578731Y2 (en) | Chemical liquid evaporator in heating evaporator | |
JPH0543411A (en) | Thermally dissipating insecticidal process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100425 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120425 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120425 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130425 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |